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Figure	 3.2:	Nickel	affinity	chromatography	was	 found	to	be	unsuccessful	 in	 the	
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Figure	 4.6:	 Spectral	 analysis	 of	 INI-43	 titrations	 shows	 possible	 secondary	
structural	 change	 of	 KpnB1	 upon	 binding	 to	 INI-43:	 Graphs	 show	 ellipticity	 vs.	















































































































































of	 genes	 with	 potential	 as	 disease	 markers	 and	 therapeutic	 targets.	 	 Our	
laboratory	 identified	 the	 eukaryotic	 nuclear	 importer	 protein	 Karyopherin	 B1	
(KpnB1),	 to	 be	 up-regulated	 in	 different	 cancer	 cell	 lines,	 including	 cervical	 and	
oesophageal	as	well	as	transformed	cells.		Inhibition	of	KpnB1	in	these	cells	using	
small	 interfering	 RNA	 (siRNA)	 resulted	 in	 significant	 cancer	 cell	 death	 via	





investigating	 a	 small	 molecule	 inhibitor	 identified	 in	 our	 laboratory,	 known	 as	
Inhibitor	 of	 Nuclear	 Import-43	 (INI-43)	 for	 its	 potential	 to	 bind	 to	 the	 nuclear	
importer,	 KpnB1.	Using	 conventional	 assays	 as	well	 as	 cutting	 edged	 techniques	
including	 circular	 dichrosim	 (CD)	 and	 isothermal	 titration	 calorimeter	 (ITC),	 an	
examination	of	INI-43	and	its	interactions	with	KpnB1	was	made.	
In	 vitro	 analysis	 showed	 that	 INI-43	 exhibits	 cytotoxic	 effects	 on	 cervical	 cancer	





Confocal	microscopy	of	 exogenous	 FRFP-KpnB1	as	well	 as	 endogenous	KpnB1	 in	
the	presence	of	 INI-43	 showed	a	 change	 in	 the	 localisation	of	 KpnB1	upon	drug	
treatment.	 	 Both	 FRFP-KpnB1	 and	 endogenous	 KpnB1	 appear	 to	 be	 prevented	




biophysical	 techniques.	 Purified	 KpnB1	 protein	 was	 prepared	 using	 GST-tagged	
purification	 methods	 and	 the	 tagged	 protein	 confirmed	 by	 mass	 spectrometry.	
Purified	GST-KpnB1	was	used	 in	drug	binding	studies	 including	circular	dichrosim	
(CD)	 isothermal	 titration	 calorimetry	 (ITC).	 	 CD	 showed	 a	 drug	 concentration	
dependant	 shift	 in	 the	 spectra	 at	 around	 233nm,	 indicative	 of	 drug	 protein	
interaction	 possibly	 occurring	 in	 a	 region	 of	 KpnB1	 containing	 aromatic	 amino	
acids.	 The	 purified	 GST-KpnB1	was	 used	 in	 ITC,	 which	 confirmed	 an	 interaction	
between	KpnB1	and	INI-43,	a	relatively	weak	interaction.		In	conclusion,	our	data	
shows	 that	 the	 small	molecule,	 INI-43	kills	 cancer	cells,	 likely	by	 interfering	with	
KpnB1	associated	nuclear	 import	pathways.	We	show	that	 INI-43	 interferes	with	
the	nuclear	localisation	of	KpnB1	itself	and	biophysical	assays	provide	evidence	for	








Despite	 continuous	 technological	 advancements	 aimed	 at	 combating	 cancer,	 it	
remains	 one	 of	 the	 leading	 causes	 of	 death	 worldwide	 and	 thus	 a	 major	
contributor	 to	 the	 total	 global	 health	 burden.	 	 The	 GLOBOCAN	 statistics	
estimated	that	in	2012	a	total	of	14.1	million	cancer	cases	occurred	worldwide,	
and	 of	 these,	 8.2	million	 cancer	 deaths	were	 estimated	 to	 have	 occurred	 that	
same	year	 (Ferlay	et	al.	2013;	Ferlay	et	al.	2015).	 	Cancer	 is	primarily	a	genetic	
disease,	 and	 this	 being	 the	 case,	 the	 dominant	 form	of	 cancer	 varies	 between	
genders	 and	 races	 and	 between	 different	 socioeconomic	 groups	 (Jemal	 et	 al.	
2011).		There	is	still	much	work	to	be	done	to	gain	control	of	the	disease	and	the	
need	for	novel	treatments	with	fewer	side	effects	remains	paramount.			
In	 developing	 countries,	 medical	 care	 is	 often	 substandard	 and	 screening	
methods	for	cancer	is	poor	or	non-existent	in	rural	areas.		In	many	rural	patients	
the	 disease	 is	 therefore	 able	 to	 progress	 unchecked	 (Hoffman	 et	 al.	 2003;	
Fiander	 2011).	 	 	 	 In	 sub-Saharan	Africa,	 the	 focus	 region	of	 this	 study,	 cervical	
cancer	 is	 the	 leading	 cause	 of	 cancer-related	 death	 in	women	 (Adewole	 et	 al.	
2013;	 Fiander	2011;	Hoffman	et	 al.	 2003).	 	 	Approximately	200	million	women	
from	the	age	of	15	years	and	older	are	at	risk	of	suffering	from	this	disease,	and	




not	 be	 a	 true	 reflection	 of	 the	 devastation	 caused	 by	 this	 disease,	 as	 many	
women	 fail	 to	 report	 to	 a	 hospital	 or	 any	 clinical	 setting	 and	 accurate	 data	
collection	in	the	region	is	consequently	also	limited	(Adewole	et	al.	2013;	Francis	
et	 al.	 2010).	 	 The	 reason	 for	 this	 disease	 presenting	 in	 such	 high	 numbers	 of	












al.	 2010).	 	 There	 has	 also	 been	 discussion	 suggesting	 that	 having	 received	 the	
vaccine	does	not	mean	women	are	one	hundred	per	cent	protected	from	cervical	









from	 the	 body	 by	 the	 immune	 system	 post	 infection	 (Adewole	 et	 al.	 2013).		
Fifteen	 problematic	 strains	 of	 the	 virus	 exist,	 however,	 that	 are	 oncogenic	 in	
nature,	 and	 these	 persist	 post	 infection,	 causing	 the	 pathologies	 commonly	
diagnosed	 in	 cervical	 cancer.	 In	 Southern	Africa,	 the	HPV	16	and	18	 strains	are	
responsible	 for	 most	 of	 the	 recorded	 cases	 of	 cervical	 cancer	 (Adewole	 et	 al.	
2013).	 	The	infection	rate	in	all	women	in	Southern	Africa	is	estimated	at	17.4%	
(Adewole	 et	 al.	 2013;	 Mbulawa	 et	 al.	 2015).	 The	 HPV	 variants	 16	 and	 18	 are	
reported	to	be	responsible	for	±70%	of	all	invasive	forms	of	cervical	cancer	cases	
recorded	worldwide	 (Adewole	et	al.	2013;	Mbulawa	et	al.	2015).	 	 The	vaccines	
Cervarix	and	Gardasil	both	provide	protection	against	HPV	16	and	18	strains.		In	





that	 in	 such	 regions	 there	 is	 a	 distinct	 benefit	 in	 administering	 the	 vaccine	 to	
young	males	as	well	as	to	females	(Giuliano	2007;	Marty	et	al.	2013;	Blomberg	et	
al.	 2015).	 	 Research	 in	 Europe	 has	 confirmed	 that	 vaccinating	 young	males	 in	





HPV	 E6	 and	 E7	 proteins,	 and	 is	 known	 to	 have	 major	 impacts	 on	 the	 gene	





90%	of	 all	 cervical	 cancers	 are	 associated	with	 infection	by	high-risk	HPV	DNA.		
The	basis	for	this	observation	is	the	fact	that	the	HPV	infection	is	associated	with	
the	 presence	 of	 the	 HPV	 oncoproteins	 E6	 and	 E7,	 which	 inhibit	 the	 normal	
functions	of	cell	cycle	proteins	p53	and	pRb	(Dyson	1998).		Typically,	p53	and	pRb	
routinely	control	cellular	transcription	during	cell	cycle;	however,	the	presence	of	
E6	 and	 E7	 leads	 to	 the	 development	 of	 a	 cancer	 phenotype	 via	 uncontrolled	
growth	and	replication	(Dyson,	1998;		van	der	Watt	et	al.,	2009).				
Gene	 expression	 studies	 in	 our	 laboratory	 using	 control	 and	 cervical	 cancer	
patient	material	identified	numerous	genes	with	altered	expression	in	the	cancer	
group	 (van	 der	 Watt	 et	 al.	 2009).	 It	 was	 proposed	 that	 some	 of	 the	 proteins	
encoded	by	 these	 genes	may	be	necessary	 for	 cancer	 cell	 survival	 and	 thus	be	
used	as	possible	anti-cancer	targets.	 	One	such	target	is	the	nuclear	transporter	




Karyopherin	proteins	 are	 implicated	 in	 assembly	of	 the	HPV	virus	 in	host	 cells,	
(Conway	 &	 Meyers	 2009;	 Zhou	 et	 al.	 1994).	 	 The	 viral	 proteins	 L1	 and	 VP1	
pentamerize	 into	capsomeres,	and	 interact	with	KpnB1	and	 its	adapter	protein	
Karyopherin	 A2	 (KpnA2)	 via	 what	 is	 known	 as	 the	 classical	 import	 pathway	
(Stanley	2015).	 	Briefly,	this	pathway	involves	the	import	of	cargo	molecules,	 in	
this	 case	 the	 viral	 proteins,	 into	 the	 nucleus	 using	 KpnB1	 partnered	 to	 the	
adaptor	 protein	 KpnA2	 via	 the	 nuclear	 pore	 complex.	 	 The	 viral	molecules	 are	
subsequently	shuttled	into	the	nucleus	of	host	cells,	and	once	inside	the	host	cell	









was	 shown	 that	 inhibition	 of	 KpnB1	 using	 siRNA	 results	 in	 cell	 death	 (van	 der	




Figure	1.1:	 	 siRNA	 induces	 cell	death	 specific	 to	 cancer	and	 transformed	with	
little	 effect	 on	 normal	 cells.	 	 Effects	 on	 relative	 proliferation	 after	 treatment	
with	 KpnB1	 siRNA,	 shown	 by	 light	 blue	 bars,	 dark	 blue	 bars	 represent	 relative	





cell	 processes,	 one	 such	 being	 the	 organisation	 of	 microtubules,	 where	 it	 is	
associated	 with	 the	 spacial	 and	 chronological	 distribution	 of	 those	 proteins	
associated	 with	 microtubule	 assembly,	 formation	 and	 organisation	 throughout	
the	cell	cycle	(Timinszky	et	al.	2002;	Angus	et	al.	2014;	Cavazza	&	Vernos	2016).	
KpnB1	is	thus	important	for	processes	such	as	mitosis	and	replication	(Timinszky	
et	 al.	 2002;	 van	 der	 Watt	 et	 al.	 2009;	 Angus	 et	 al.	 2014).	 	 Previous	 work	
















KpnB1	 is	 important	 for	 the	growth	and	 survival	 of	 cancer	 cells,	 and	 that	 small-







movement	of	molecules	between	 the	nucleus	and	 the	 cytoplasm	of	eukaryotic	
















The	 cytoplasmic	 filaments	 have	 loose	 ends,	 while	 the	 nuclear	 filaments	 are	
joined	 in	a	distal	 ring,	 forming	a	structure	known	as	 the	nuclear	basket	 (Figure	
1.2	 a)	 (D’Angelo	 &	 Hetzer	 2008).	 Functionally,	 the	 nuclear	 pore	 facilitates	 the	
movement	of	transport	proteins	such	as	KpnB1	and	KpnA2	and	their	cargo	into	
the	nucleus.		In	the	process	of	passing	through	the	NPC,	these	proteins	interact	








Figure	 1.2:	 The	 nuclear	 pore	 complex	 (NPC)	 is	 a	 complicated	 structure	
comprised	 of	 smaller	 proteins	 known	 as	 nucleorporins	 (Nups).	 (a)	 Schematic	
diagram	 of	 the	 NPC	 showing	 the	 fundamental	 structures;	 (b)	 Location	 of	 the	








The	mechanisms	 involved	 in	 the	 translocation	of	 the	Karyopherin	proteins	with	
associated	 cargo	 remains	 uncertain.	 Within	 the	 NPC	 are	 a	 group	 of	 proteins,	
which	 are	 rich	 in	 phenylalanine	 and	 glycine	 (FG	 repeats)	 (Ma	 &	 Yang	 2010).		
These	 FG	 repeats	 most	 likely	 assist	 in	 the	 transport	 process,	 because	 of	 their	
interaction	with	the	cargo	molecules	as	they	pass	through	the	NPC	 (Ma	&	Yang	
2010;	Koh	&	Blobel	2015).	
1.5	 Karyopherin	 B1	 and	 Transport	 Through	 the	 Nuclear	 Pore	 Complex:	
Nucleocytoplasmic	Transport		
The	nuclear	envelope	(NE)	provides	a	protective	barrier	for	the	nuclear	material.		
Movement	 through	 this	 channel	 is	 controlled	 by	 the	 NPC	 (Liu	 &	 York	 2001).	
Shuttling	 proteins	 such	 as	 KpnB1	 are	 able	 to	 enter	 and	 exit	 the	 nucleus	 along	
with	 their	 respective	 cargo	molecules	 via	 this	 channel	 (Lott	&	Cingolani	 2011).	
This	structural	feature	maintains	and	protects	the	quality	of	the	genetic	material	
of	 the	cell	 (Liu	&	York	2001).	 	 It	also	enables	stringent	regulation	of	genetically	
controlled	processes	within	cells	such	as	the	transcription	of	NFAT	in	response	to	
intracellular	 calcium	 release	 in	 T-cells	 (Feske	 et	 al.	 2007;	 Gwack	 et	 al.	 2007).		
Such	 control	 allows	 transcription	 factors	 access	 to	 the	 nucleus	 in	 response	 to	
certain	 stimuli,	 allowing	 cells	 to	 produce	 mRNA	 for	 protein	 translation	 in	 a	
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discriminant	and/or	 regulated	 fashion	 (Hetzer	&	Wente	2009;	Akhtar	&	Gasser	
2007).	
For	 a	 cell	 to	 respond	 to	 stimuli,	 signalling	molecules	must	 enter	 and	 leave	 the	
nucleus	 (Akhtar	 &	 Gasser	 2007).	 	 This	 is	 done	 through	 the	 NPC,	 selectively	
allowing	certain	molecules	entry	and	exit	through	the	NE	(Akhtar	&	Gasser	2007).		
The	 well-described	 method	 of	 transportation	 into	 the	 nucleus,	 the	 ‘classical’	
pathway,	 involves	 interaction	of	KpnB1	with	the	adaptor	protein	KpnA2	(Figure	
1.3	 b)	 (Timinszky	 et	 al	 2002).	 	 In	 this	 mode	 of	 importation,	 the	 nuclear	
localisation	 sequence	 (NLS)	 on	 the	 cargo	 molecule	 is	 recognised	 and	
subsequently	 binds	 to	 the	 adaptor	 protein	 KpnA2,	which	 itself	 binds	 to	 KpnB1	
(Conti,	E.,	Muller,	C.	W.	and	Stewart	M.	2005).	 	This	 initial	stage	of	the	process	
takes	place	in	the	cytoplasm.		Once	in	this	bound	conformation,	the	Karyopherin	
complex	 is	able	 to	dock	on	 the	outside	of	 the	NPC;	 following	 this,	 transport	of	
the	complex	through	the	NPC	into	the	nucleus	via	the	interaction	of	KpnB1	with	
several	nucleoporins	is	facilitated	(Clarke	P.	L.		and		Zhang	C.	2008).		Once	in	the	
nucleus,	 disassociation	 of	 the	 cargo	 occurs	 upon	 binding	 of	 RanGTP	 and	 the	
cargo	is	freed	to	carry	out	its	function	within	the	nucleus	(Conti,	E.,	Muller,	C.	W.	
and	 Stewart	M.	 2005).	 The	 importer	 proteins	 are	 eventually	 recycled	 into	 the	
cytoplasm,	with	KpnB1	coupled	to	RanGTP	and	KpnA2	complexed	to	RanGTP	and	
its	 export	 factor	Crm1	 (Clarke	P.	 L.	 and	 Zhang	C.	 2008).	 	 In	 the	 cytoplasm,	 the	




GTP	 provides	 the	 necessary	 energy	 for	 these	 transport	 cycles	 and	 is	 therefore	
the	energy	source	for	this	process.			
The	 transport	 of	 cargo	 through	 the	 NPC	 is	 dependent	 on	 the	 concentration	
gradient	 of	 RanGTP	 (Chook	 &	 Katherine	 E	 Süel	 2011).	 	 In	 the	 cytoplasm,	 the	
import	factors	bind	to	their	cargo	in	the	absence	of	RanGTP	(Chook	&	Katherine	
E	Süel	2011;	Yuh	&	Blobel	2001).	 	The	nuclear	exporters	will	however	only	bind	

















An	 additional	 mechanism	 by	 which	 molecules	 are	 able	 to	 enter	 the	 nucleus	
involves	the	direct	interaction	of	the	NLS	located	on	the	cargo	with	KpnB1.		This	
non-classical	 transport	 mechanism	 happens	 independently	 of	 the	 binding	 of	
KpnA2	(Lott	&	Cingolani	2011).	The	cargo	still	requires	RanGTP	to	bind	to	KpnB1	
so	that	it	can	dissociate,	and	the	recycling	of	KpnB1	and	RanGTP	is	seen	to	occur	





promotes	 binding	 of	 the	 cargo	 to	 either	 the	 adaptor	 molecule	 KpnA2	 (in	 the	
classic	 pathway)	 or	 directly	 to	 KpnB1	 (in	 the	 non-classic	 pathway),	 thereby	
allowing	the	molecules	to	pass	through	the	NPC	into	the	nucleus	(Yoneda	et	al.	
1999).	 	 The	 NLS	 was	 first	 documented	 in	 1984,	 when	 it	 was	 reported	 that	 a	
molecular	 sequence	 existed	 which	 was	 responsible	 for	 transporting	 the	 SV40	
large-T	antigen	 into	 the	nucleus	 (Kalderon	et	 al.	 1984).	 	After	 its	discovery	 the	
sequence	 became	 known	 as	 the	 nuclear	 localisation	 sequence	 (NLS)	 and	 was	
known	 to	 have	 two	 important	 characteristics.	 	 Firstly,	 it	 is	 small	 (about	 seven	





This	 particular	 group	of	NLS	became	known	as	 the	 classical	NLS.	 	 Classical	NLS	
can	 be	 either	 monopartite	 (single	 amino	 acid	 sequence)	 or	 bipartite	 (double	
amino	acid	 sequence)	 (Kobayashi	&	Matsuura	2013;	Cautain	et	 al.	 2015).	 	 This	
group	of	NLS	 interact	with	KpnA2	and	 function	 in	 the	classical	 import	pathway	
(Lott	&	Cingolani	2011).			
The	 non-classical	 NLS	 differ	 in	 that	 they	 have	 more	 complex	 amino	 acid	
sequences,	and	their	tertiary	structure	may	also	be	important	for	the	recognition	
of	their	target	sequences	(Lott	&	Cingolani	2011;	Conti	et	al.	1998).		The	Importin	








import	 of	 proteins	 and	 mRNA	 molecules	 into	 the	 nucleus	 of	 eukaryotic	 cells	
(Chook	 &	 Katherine	 E	 Süel	 2011).	 	 In	 humans,	 this	 transport	 process	 is	
unidirectional	and	requires	different	transport	proteins	to	control	and	maintain	
the	export	process.		The	bound	crystal	structure	of	KpnB1	has	been	determined,	
which	 allows	 insight	 into	 the	 three-dimensional	 structure	 of	 the	 protein	 and	





KpnB1	is	a	relatively	 large	protein	of	around	100	kDa	in	molecular	weight.	 	 It	 is	
comprised	of	19	HEAT	repeats	(Huntingtin,	elongation	factor	3,	PR65/A	sub-unit	
of	protein	phosphates	2A,	 and	 the	TOR	 lipid	 kinase).	 	HEAT	 repeats	 are	paired	
antiparallel	 alpha	 helices	 linked	 by	 a	 tandem	 loop,	 the	 pitch	 of	 which	 could	
change	 dramatically	 with	 the	 binding	 of	 substrates	 (Lee	 et	 al	 2000).	 	 This	
flexibility	is	believed	to	be	a	key	factor	in	allowing	KpnB1	to	interact	with	not	just	




















The	 HEAT	 repeats	 stack	 together	 with	 a	 slight	 clockwise	 twist,	 creating	 a	










Work	 done	 in	 our	 laboratory	 and	 elsewhere	 has	 shown	 that	 one	 of	 the	 key	
functions	 of	 KpnB1	 is	 its	 role	 in	 maintaining	 cancer	 cell	 survival	 and	 for	
participating	in	cellular	replication	(van	der	Watt	et	al.	2009;	Angus	et	al.	2014;	




al.	 2013).	 	 The	 design	 of	 the	 small-molecule	 inhibitor	 used	 in	 this	 project	was	
based	on	the	published	crystal	structure	of	KpnB1	bound	to	RanGTP	and	KpnA2.	
When	bound	to	KpnA2,	KpnB1	takes	on	a	twisted	‘snail-shell-like’	conformation	




alpha	helices	able	 to	 rotate,	avoiding	steric	 interactions,	 in	 the	case	of	RanGTP	
interactions	 (Lee,	 S.	 J.	 et	 al	 2000).	 	 The	 acidic	 loop,	 on	 HEAT	 repeat	 8,	 is	
important	 for	 substrate	 binding	 and	 disassociation	 (Cook	 et	 al,	 2007).	 The	
unbound	 form	of	 KpnB1	 has	 not	 been	 determined	 and	 all	 compounds	 used	 in	
this	 study	 have	 been	 designed	 based	 on	 the	 bound	 form	 of	 KpnB1	 (Lee	 et	 al.	
2000).	 	 It	 is	anticipated	that	targeting	KpnB1	be	effective	 in	 inhibiting	 its	action	
(Cingolani	et	al.	1999;	van	der	Watt	et	al.	2013).		
1.8	 Discovery	of	Small-Molecule	Inhibitors	with	Anti-Cancer	Activity	
Paul	 Ehrlich	 first	 devised	 the	 term	 ‘magic	 bullet’	 in	 the	 1800s	 as	 a	 chemical	
therapy	which	was	extremely	specific	in	its	action	and	interacted	directly	with	its	
target	 (Imai	&	 Takaoka	 2006).	 	 Since	 then,	 targeted	 drug	 therapies	 have	 been	
successfully	integrated	into	conventional	cancer	treatment	in	the	form	of	small-
molecule	 inhibitors,	 and	 the	 manner	 in	 which	 cancer	 is	 being	 treated	 now	
includes	 combination	 therapies	 (Imai	 &	 Takaoka	 2006).	 	 As	 there	 is	 a	 high	
demand	 for	 treatments	with	 reduced	side	effects	and	 low	cross-resistance,	 the	
need	for	novel	compounds	that	are	effective	anti-cancer	agents	is	equally	urgent.		
The	 advent	 of	 technologies	 such	 as	 x-ray	 crystallography	 and	 genomic	 and	
proteomic	 sequencing	 has	 aided	 the	 discovery	 and	 production	 of	 new	
compounds	with	specific	targets	(Durrant	&	McCammon	2011).		
Novel	cancer	therapeutic	agents	can	take	the	form	of	small-molecule	inhibitors,	





Protein	 kinases	 catalyse	 intracellular	 reactions	 by	 transferring	 a	 terminal	
phosphate	 of	 ATP	 to	 substrates	 frequently	 on	 a	 serine	 or	 a	 threonine	 residue	






An	 example	 of	 a	 well-known	 small-molecule	 kinase	 inhibitor	 in	 use	 today	 is	
Imatinib	 (Gleevec,	GSK)	 (Druker	 2002a).	 	 Imatinib	 is	 a	 tyrosine	 kinase	 inhibitor	
targeted	at	the	mutant	kinase	created	by	the	inversion	of	the	BCR:ABL	genes	on	
the	 Philadelphia	 chromosome	 in	 chronic	 myeloid	 leukaemia	 patients	 (Druker	
2002b;	 Druker	 2002a).	 	 Figure	 1.5	 shows	 Imatinib	 (pink)	 bound	 to	 its	 target	
tyrosine	 kinase	 in	 the	 ATP	 binding	 pocket	 (Van	 Montfort	 &	 Workman	 2009;	
Zhang	 et	 al.	 2009).	 	 Imatinib	 binds	 to	 the	 glycine	 rich	 region	 (yellow)	 with	
hydrogen	 bonds	 and	 in	 so	 doing	 prevents	 the	 activation	 segment	 (red)	 from	




inhibiting	 cancer	 cell	 proliferation	 (Van	Montfort	&	Workman	 2009).	 	 Gefitinib	
has	been	shown	to	be	effective	with	Her1,	Her2	and	Her3	overexpressing	cancer	
20	
patients,	 including	 breast	 and	 non-small-cell	 lung	 cancers	 (van	 Montfort	 and	
Workman	 2009).	 	 These	 targeted	 therapies	 have	 been	 shown	 to	 be	markedly	
successful	 because	 they	 function	 in	 such	 a	 specific	 manner.	 	 They	 inhibit	 the	
cancer	cell’s	own	molecular	machinery	which	 is	mandatory	for	 its	survival,	thus	
leading	to	cell	death	(Van	Montfort	&	Workman	2009;	Zhang	et	al.	2009).	
Figure1.5:	 Imatinib	binds	 specifically	 to	 the	mutant	 Tyrosine	Kinase	 forcing	 it	
into	the	inactive	conformation.		Imatinib	(pink)	binds	to	the	ATP	binding	pocket	
of	 the	 mutant	 tyrosine	 kinase	 via	 hydrogen	 bonds.	 	 The	 target	 activation	







been	 observed	 to	 be	 up-regulated	 in	 some	 forms	 of	 cancer	 (Gerecitano	 2014;	
van	der	Watt	 et	 al.	 2009).	 	 It	 has	been	 suggested	 that	 the	 increased	export	of	
tumour-suppressor	 proteins,	 including	p53,	 p21,	 p27,	 pRb,	 FOXO	and	 IΚB,	may	






death	 by	 apoptosis.	 The	 compound	 Selinexor	 has	 been	used	 in	 phase	 I	 clinical	
trials	for	use	in	multiple	myeloma,	AML,	CLL,	and	various	subtypes	of	NHL	(Abdul	
Razak	et	al.	2016).	These	compounds	may	have	use	not	just	in	cancer	treatment;	






cancer	 approach.	 	 In	 our	 laboratory,	 we	 aimed	 to	 identify	 small-molecule	
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inhibitors	 of	 nuclear	 import	 by	 targeting	 KpnB1	 as	 an	 anti-cancer	 approach.	
Research	in	our	lab	has	previously	identified	a	parent	compound	using	a	rational	
drug-design	 approach	 which	 is	 a	 method	 commonly	 used	 to	 identify	 small-
molecule	 inhibitors	 (Huggins	et	al.	2012).	 	There	are	two	types	of	 rational	drug	
design:	 ligand-based	 methods	 and	 structure-based	 methods	 (Huggins	 et	 al.	
2012).		In	this	approach	a	structure-based	method	was	used:	a	technique	which	
involves	 a	 process	 of	 ‘reverse	 engineering'	 drugs,	 based	 on	 the	 known	 crystal	
structure	of	a	 target	protein,	using	 in	silico	modelling	methods	 together	with	a	
large	database	of	possible	drug	candidates	 to	 identify	 suitable	 test	 compounds	
(Huggins	et	al.	2012).		Compounds	identified	as	having	potential	to	bind	a	specific	
target	are	tested	in	vitro	and	in	vivo	to	assess	the	biological	effects	of	the	drugs	
and	 the	binding	 affinities	 (Huggins	 et	 al.	 2012).	 This	may	 include	making	 small	
changes	 to	 candidate	 molecules	 having	 the	 desired	 qualities,	 which	 are	 then	
pursued	further.	The	chemical	structure	of	the	parent	drug	compound	is	altered	
to	 improve	 the	efficacy	of	 the	 compound	and	 in	 some	 cases	 reduce	undesired	
side	effects	(Huggins	et	al.	2012).	The	use	of	rational	drug	design	in	recent	years	






the	 way	 it	 functions	 in	 vitro.	 	 Of	 particular	 interest	 was	 whether	 the	 small-
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molecule	 inhibitor	 being	 examined	 was	 directly	 interacting	 with	 KpnB1.	 	 	 The	
drug	 design	 process	 completed	 by	 our	 collaborators	 at	 the	 University	 of	
Louisville	Kentucky,	made	use	of	the	known	crystal	structure	of	KpnB1	bound	to	
KpnA2	 and	 Ran	 to	 screen	 an	 in	 silico	 library	 for	 small	 molecules	 with	 the	
potential	 to	 bind	 to	 KpnB1.	 	 The	 region	 of	 KpnB1	 targeted	 was	 based	 on	
mutagenic	studies	that	showed	a	loss	in	function	of	KpnB1	when	alterations	are	
incorporated	 into	 the	 regions	 where	 the	 binding	 site	 overlap	 of	 KpnA2	 and	
RanGTP	 occurs	 between	 HEAT	 repeats	 5	 and	 6	 on	 the	 protein	 (Figure	 1.6)		
(Cingolani	et	al.	1999).		
Figure1.6:	Region	of	interest	for	drug	binding	is	between	HEAT	repeats	5	and	6	





1. The	 known	 crystal	 structure	 of	 bound	 KpnB1	 was	 screened	 by	 our	
collaborators	 against	 an	 in	 silico	 library	 of	 12	662	570	 compounds	 for	 its	
ability	 to	 bind	 to	 small	 molecules.	 Of	 the	 compounds	 identified	 with	
potential	 to	bind	KpnB1,	previous	members	of	our	 laboratory	 tested	 forty-
seven	 in	 in	 vitro	experiments	using	CaSki	 cervical	 cancer	 cells.	Compounds	
identified	 by	 the	 in	 silico	 screen	 were	 first	 tested	 for	 their	 effects	 on	 cell	
death	and	proliferation.		Following	this,	compounds	with	the	lowest	IC50		(i.e.	
<50μM)	were	tested	for	their	ability	 to	block	nuclear	membrane	transport.		
Only	 ten,	 of	 the	 compounds	 tested	 had	 an	 IC50	 <50uM,	 and	 of	 these	 only	
three	compounds	–	including	one	named	inhibitor	of	nuclear	import	43	(INI-
43),	 3-(1H-benzimidazol-2-yl)-1-(3-dimethylaminopropyl)pyrrolo[5,4-
b]quinoxalin-2-amine	 –	 showed	 both	 cytotoxic	 effects	 and	 the	 ability	 to	
block	 nuclear	 transport	 as	 demonstrated	 by	 immunofluorescence	
microscopy	 and	 cell	 fractionation	 studies	 (van	 der	Watt	 et	 al.	 2016).	 	 The	
long-term	goal	of	his	research	is	to	examine	candidate	KpnB1	targeted	small	
molecules	 which	 were	 previously	 identified	 using	 a	 rational	 drug	 design	
approach	and	if	they	could	have	potential	as	future	anti-cancer	agents.		This	
particular	 study	 is	 focused	 on	 investigating	 whether	 or	 not	 the	 lead	
compound	 INI-43	 interacts	 with	 KpnB1	 and	 attempts	 to	 examine	 the	
mechanisms	 and	 characteristics,	 which	 are	 responsible	 for	 enabling	 this	
possible	 interaction.	 	 If	 INI-43	was	 found	 to	 be	 interacting	with	 the	 target	








changes	 to	 the	 localisation	 of	 KpnB1	 in	 cells	 using	 confocal	 microscopy	 was	
performed.	 	We	examined	the	effects	of	 INI-43	on	cells	expressing	endogenous	




optimised	 using	 various	 chromatographic	 techniques.	 	 The	 methods	 used	
included	 His-affinity	 tag	 protein	 purification,	 anion	 exchange	 chromatography,	
gel	filtration	chromatography	and	GST-affinity	tag	protein	purification.		The	final	
protein	product	was	isolated	on	SDS-PAGE	and	confirmed	via	mass	spectrometry.		
Chapter	 4	 is	 a	 biophysical	 analysis	 of	 the	 in	 house	 purified	 protein	 with	 the	
experimental	 drug	 INI-43	 to	 determine	 whether	 there	 is	 a	 direct	 interaction	















b. Determining	 the	 effects	 of	 INI-43	 on	HeLa	 and	 CaSki	 cell	 proliferation	 and	
the	induction	of	cell	death.	
c. Investigating	 the	 effects	 of	 INI-43	 on	 the	 activity	 of	 NFAT,	 a	 KpnB1	 cargo	
protein.	
d. Investigating	the	effect	of	INI-43	on	KpnB1	sub-cellular	localisation.		
3. To	generate	KpnB1	clones	 to	be	used	 in	 the	preparation	of	purified	KpnB1	
for	biophysical	analysis	of	drug–protein	interaction.		














siRNA	 showed	 that	 the	 knock-down	 of	 KpnB1	 expression	 inhibits	 proliferation	 of	
cervical	cancer	cells	and	is	associated	with	cell	death	via	apoptosis	(van	der	Watt	et	al.	
2009;	van	der	Watt	et	al.	2011;	Angus	et	al.	2014);	KpnB1	is	implicated	in	mitosis	and	
spindle	 assembly	 and	 its	 inhibition	 has	 thus	 been	 shown	 to	 affect	 cell	 cycle	
progression.	
While	no	currently	known	therapeutic	drugs	specifically	target	KpnB1	as	an	anti-cancer	
agent,	 there	 are	 two	 experimental	 compounds,	 Karyostatin	 and	 Importazole,	 that	
inhibit	 the	 KpnB1–RanGTP	 interaction	 in	 the	 classical	 import	 pathway	 (Jonathan	 F	
Soderholm	et	al.	2011;	Bird	et	al.	2013;	Jans	et	al.	2011).	Both	compounds	have	been	
used	 to	 study	cell	 cycle	and	chromatin	assembly	 (Jans	et	al.	2011).	 	 Importazole	 is	a	
2,4-diaminoquinoxaline	(Figure	2.1	A)	and	Karyostatin	is	a	pyrole	compound,	which	is	a	
larger	molecule	(and	subsequently	reported	also	to	be	bulkier)	(Figure	2.1	B)	(Jonathan	
F	 Soderholm	et	 al.	 2011)	 (Bird	 et	 al.	 2013).	 	 There	 is	 limited	 knowledge	of	 the	 anti-
cancer	potential	of	these	molecules.	
As	our	 laboratory	has	an	 interest	 in	 targeting	KpnB1	as	an	anti-cancer	approach,	we	
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the	 KpnB1	 target	 region	 of	 interest.	 	 The	 computational	 screening	 analysis	 was	
performed	 by	 our	 collaborators	 at	 the	Molecular	Modelling	 Facility	 of	 the	 James	
Graham	 Brown	 Cancer	 Centre,	 University	 of	 Louisville,	 Kentucky,	 USA,	 using	 a	







database	 (Irwin	&	Shoichet	2005)	was	 investigated	against	 the	 regions	of	 interest	
using	the	1ibr	structure,	based	on	the	methods	described	in	(Holt	et	al.	2009).	The	
compounds	 were	 ranked	 according	 to	 their	 predicted	 KpnB1-binding	 affinity	 and	
forty-seven	 of	 the	 top-scoring	 candidates	 were	 subsequently	 purchased	 from	
MolPort	 (Riga,	 Latvia),	 ChemBridge	 (San	 Diego,	 CA,	 USA)	 and	 Enamine	 (Kiev,	
Ukraine).	 	 	 Our	 laboratory	 screened	 these	 compounds	 for	 their	 ability	 to	 block	
nuclear	import,	as	well	as	their	cytotoxic	effects	on	normal	and	cancer	cells	(van	der	
Watt	et	al.	2016).		Inhibitor	of	Nuclear	Import-43,	INI-43	(3-(1H-benzimidazol-2-yl)-	
1-(3-dimethylaminopropyl)pyrrolo[5,4-b]quinoxalin-2-amine)	 (Figure	 2.2)	 exhibited	
both	 cytotoxic	 and	 nuclear	 import	 inhibitory	 effects	 and	 was	 obtained	 from	
Chembridge	 (ZINC	 identification	 no.	 20547783)	 (van	 der	 Watt	 et	 al.	 2013)	 	 and	
Stowell,	2011,	MSc	Dissertation.		
INI-43	 is	 a	 quinoxaline	 based	 compound	 and	 previous	 research	 has	 shown	 that	
quinoxaline	based	 compounds	have	potential	 as	 anti-proliferative	on	 cancer	 cells,	
(Pereira	et	al.	2014).	 	 INI-43	was	one	of	 three	compounds	 identified	 to	have	both	
cancer	cell	killing	effects	and	inhibitory	effects	on	nuclear	import	pathways	(Stowell,	






Figure	 2.2:	 Inhibitor	 of	 nuclear	 transport	 43	 (INI-43).	 Chemical	 structure	 of	 INI-43	








in	 the	 past	 as	 a	 colorimetric	 assay,	 able	 to	 determine	 cellular	 viability	 based	 on	 the	
colour	change	of	the	MTT	based	on	the	cells	metabolic	activity.		This	therefore	allows	









To	monitor	 the	effects	of	 INI-43	on	proliferation	we	again	used	 the	MTT	assay	using	
both	HeLa	and	CaSKi	cells.		Cells	were	grown	in	0,	5,	10	and	15	μM	INI-43	over	a	period	






via	 INI-43	 treatment	 occurred	 via	 the	 apoptotic	 pathway.	 	 To	monitor	 whether	 cell	
death	occurred	via	apoptosis,	we	used	 the	 standard	method	of	measuring	apoptotic	
cell	death	using	Poly	 (ADP-ribose)	polymerase-1	(PARP-1)	cleavage	 in	HeLa	and	CaSki	
cells.	 Increasing	doses	of	 INI-43	 	 (0	μM,	5	μM	and	10	μM)	were	selected	and	used	to	
treat	 both	 cell	 lines	 for	 a	 period	 of	 24	 hours.	 	 A	 dose	 of	 15	μM	 INI-43	 resulted	 in	
substantive	 cell	 death	 and	 degradation	 of	 all	 proteins	 including	 the	 loading	 control	
(data	 not	 shown).	 	 	When	 cells	 treated	 with	 15	μM	 INI-43,	 were	 viewed	 under	 the	
inverted	light	microscope,	we	observed	no	live	cells,	only	floating	dead	cells.		We	thus	




PARP-1	 is	 downstream	 of	 caspase	 3/7	 which	 activates	 the	 cleavage	 of	 PARP-1	 on	
upstream	 signals	 from	 the	 cell’s	 mitochondria.	 Once	 PARP-1	 becomes	 cleaved	 it	













response	 to	 increasing	 concentrations	 of	 INI-43.	 Half	 maximal	 inhibitory	
concentration	(IC50):	IC50	of	INI-43	in	HeLa	cells	found	to	be	6.23μM	(Figure	2.3A).	The	
IC50	of	INI-43	in	CaSKi	cells	found	to	be	6.82	μM	(Figure	2.3B).	
IC50 of INI-43 in HeLa cells
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IC50 of INI-43 in CaSki cells
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MTT proliferation curve: HeLa cell line INI-43 treatment
















MTT proliferation curve: Caski cell line INI-43 treatment













































Figure	 2.5:	 INI-43	 induces	 cells	 death	 via	 apoptosis	 as	 shown	 by	 PARP-1	
cleavage:	 	Western	blot	analysis	showing	and	increase	in	cleavage	of	pre-cursor	
PARP-1	 with	 increasing	 doses	 of	 INI-43	 in	 both	 HeLa	 and	 CaSki	 cell	 lines.	 	 (A)	
PARP-1	 cleavage	 in	 HeLa	 cells;	 (B)	 PARP-1	 cleavage	 in	 CaSki.	 Western	 blot	
analysis	of	PARP	cleavage	in	cell	lysates	obtained	from	control,	5	μM	and	10	μM	
INI-43	treated	CaSki	and	HeLa	cells.	Cells	were	treated	for	24hrs.	β-Tubulin	was	
used	 as	 a	 loading	 control.	 Results	 shown	 are	 representative	 of	 experiments	
performed	 at	 least	 three	 independent	 times.	 (C)	 Histogram	 showing	


























































































































target	 protein	 and	 (ii)	 investigating	 KpnB1	 localisation	 after	 INI-43	 treatment.	
The	activity	of	NFAT,	a	known	KpnB1	target	protein,	was	investigated	as	a	marker	
of	 KpnB1-mediated	 nuclear	 import.	 A	 NFAT-luciferase	 reporter	 plasmid	
containing	 three	 tandem	 repeats	 of	 a	 30	bp	 fragment	 of	 the	 IL-2	 promoter	
known	to	bind	NFAT	was	used	in	luciferase	assays	as	a	measure	of	NFAT	nuclear	
import	 (Addgene	plasmid	#10959).	HeLa	 cells	were	 transfected	with	 the	NFAT-
responsive	plasmid	and	 treated	with	5,	 10	and	15	μM.	Cells	were	 treated	with	
Ionomycin	 and	 PMA	 to	 induce	 NFAT	 nuclear	 translocation	 and	 associated	
transcriptional	 activity.	 Ionomycin	 induces	 the	 release	 of	 intracellular	 calcium	
stores	and	stimulates	NFAT	translocation	to	the	nucleus	(Beals	et	al.	1997).	
Our	data	shows	that	PMA/Ionomycin	treatment	resulted	in	NFAT	activation	(i.e.	
nuclear	 translocation).	 A	 dose-responsive	 decrease	 in	 NFAT	 activity	 was	
observed	 with	 increasing	 concentration	 of	 INI-43	 (Figure	 2.6).	 From	 this	 we	
inferred	that	 the	decrease	 in	NFAT	activity	was	a	result	of	decreased	 import	of	
NFAT	in	the	presence	of	INI-43.		Since	NFAT	relies	on	KpnB1	to	gain	entry	into	the	

























Figure	 2.6:	 INI-43	 inhibits	 nuclear	 import	 of	 the	 KpnB1	 target	 protein	 NFAT.		
HeLa	cells	were	transfected	with	the	NFAT-luciferase	reporter	plasmid	(Addgene	
plasmid	 #10959),	 then	 treated	 with	 5	 and	 10	μM	 of	 INI-43.	 	 After	 stimulating	
with	Ionomycin	and	PMA,	the	relative	NFAT	activity	was	quantified	by	expressing	
luminescence	 relative	 to	 that	 of	 the	 transfection	 control,	 TK-renilla-luciferase.		








































Having	 observed	 the	 ability	 of	 INI-43	 to	 inhibit	 the	 activity	 of	 KpnB1	 target	
proteins,	we	also	investigated	the	effects	 INI-43	of	on	the	localisation	of	KpnB1	





nucleus	 (Figure	2.7A).	Treatment	of	cells	with	 INI-43	 for	45	minutes	resulted	 in	
relocation	of	KpnB1	towards	the	peri-nuclear	and	cytoplasmic	areas	of	the	cells	
(Figure	 2.7B).	 	 Similar	 observations	were	made	with	 the	 60-minute	 treatment,	
with	cells	showing	an	intense	peri-nuclear	localization	of	KpnB1	forming	a	“ring-
like”	 structure	 (Figure	 2.7C).	 	 With	 the	 180-minute	 INI-43	 treatment,	 KpnB1	
localisation	 appeared	 to	 be	 predominantly	 cytoplasmic	 (Figure	 2.7D).	 These	










we	 also	 explored	 the	 effects	 of	 INI-43	 on	 the	 localisation	 of	 exogenously	
expressed	 far-red	 fluorescent-labelled	 KpnB1.	 	 The	 first	 step	was	 to	 prepare	 a	
fluorescent-labelled	KpnB1	construct	(FRFP-KpnB1),	accomplished	by	cloning	the	
KpnB1	insert	into	the	pmKate-2c	plasmid.	Full-length	KpnB1	was	amplified	using	
PCR	 from	 pGEX6-KpnB1	 (a	 plasmid	 constructed	 in	 this	 project	 for	 protein	





by	 enzymatic	 digestion	 using	 Sac11	 and	BamH1	 (Figure	 2.8B).	 The	 presence	 of	
the	insert	was	also	confirmed	by	sequence	analysis.	To	confirm	expression	of	the	
tagged	protein,	the	plasmids	were	transfected	into	HeLa	cells	and	protein	lysates	
extracted	 followed	 by	 western	 blot	 analysis.	 Results	 showed	 that	 transfected	
cells	were	positive	 for	both	endogenous	KpnB1	and	tagged	FRFP-KpnB1	(Figure	
2.8C).	 	 Cells	 transfected	 with	 FRFP-KpnB1	 and	 treated	 with	 INI-43	 were	
subsequently	 used	 to	 monitor	 the	 effects	 of	 INI-43	 on	 the	 FRFP-KpnB1	 sub-
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cellular	 localisation	 using	 confocal	 microscopy.	 	 Our	 results	 show	 that	 INI-43	
treatment	 results	 in	 peri-nuclear	 and	 cytoplasmic	 localisation	 of	 FRFP-KpnB1	
(Figure	2.9),	very	similar	to	that	observed	with	endogenous	KpnB1.	The	chemical	









Figure	 2.7:	 Effects	 of	 INI-43	 treatment	 on	 localisation	 of	 endogenous	 KpnB1.	
Immunofluorescent	 analysis	 showing	 INI-43	 treatment	 alters	 KpnB1	 subcellular	
localisation.	HeLa	cells	were	treated	with	5	μM	INI-43	for	45	minutes,	60	minutes	
and	120	minutes,	and	fluorescent	images	captured	by	confocal	microscopy.	 	 (A)	
Control/untreated	 cells.	 	 (B)	 45	 min	 treatment	 with	 5	μM	 INI-43.	 (C)	 60	 min	
treatment	with	5	μM	INI-43.	(D)	180	min	treatment	with	5	μM	INI-43.	The	arrows	
show	how	the	protein	re-localises	from	the	nucleus	in	control/untreated	cells	to	














Figure	 2.8:	 	 Preparation	 of	 FRFP-pmKate2c	 plasmid.	 (A)	 PCR	 amplification	 of	
2.5	kbp	KpnB1.	(B)	Restriction	digestion	to	visualise	KpnB1	release	from	the	final	




























































































Figure	 2.9:	 	 Confocal	microscopy	 shows	 relocation	 of	 exogenously	 expressed	
KpnB1	post			treatment	with	INI-43.	HeLa	cells	transfected	with	FRFP-KpnB1	and	
treated	 for	 24	hours	with	 INI-43.	 	A	 similar	 pattern	 to	 that	of	 the	endogenous	
KpnB1	(Figure	2.7)	observed	in	that	FRFP-KpnB1	localises	in	the	peri-nuclear	and	
cytoplasmic	 region.	 A	 distinct	 peri-nuclear	 “ring-like”	 structure	 is	 formed	 post	
treatment	with	 INI-43	 (distinguished	 by	white	 arrows).	 INI-43	 itself	 fluoresces,	
and	appears	to	localise	throughout	the	cell.	







Figure	 2.10:	 Immunofluorescent	 analysis	 of	 INI-43	 and	 FRFP-KpnB1	 in	 HeLa	
cells.	 (A)	HeLa	cells	 transfected	FRFP	only	 (scale	20μM).	 	 (B)	HeLa	cells	 treated	
with	5	μM	INI-43	for	20	min	(scale	10	000μM).	(C)	HeLa	cells	treated	with	5	μM	












We	had	earlier	established	 the	duration	 for	 treatment	of	 cells	with	 INI-43	 that	
would	show	optimal	effects	on	exogenously	expressed	FRFP-KpnB1	in	HeLa	cells.		
This	 optimal	 treatment	 duration	 was	 identified	 as	 being	 between	 30	 and	 45	
minutes	 -	 the	 duration	 within	 which	 the	 effects	 of	 changes	 in	 FRFP-KpnB1	
localisation	were	visualised	most	 clearly.	We	adopted	 this	 timing	 in	using	FRET	
photobleaching	 analysis	 to	 examine	 whether	 or	 not	 the	 KpnB1	 was	 directly	
interacting	with	INI-43.			
We	used	FRFP-KpnB1	 in	 FRET	photobleaching	experiments,	 as	 spectral	 analysis	
showed	 that	 INI-43	 and	 the	 red	 fluorescence	 in	 pmKate-2C	 had	 overlapping	
excitation	 and	 emission	 spectra,	 which	 is	 a	 necessary	 requirement	 for	 FRET	
(figure	2.11	A).	 	When	performing	FRET	photobleaching	 it	 is	 important	that	the	
excitation	and	emission	spectra	of	the	donor	overlap	with	those	of	the	acceptor.		
During	 the	 assay	 lasers	 to	 excite	 the	donor	 fluorphore,	 causing	 it	 to	 fluoresce.	
Photons	 from	 the	 excited	 donor,	 of	 the	 correct	 wavelength	 are	 released	 and	
excite	 the	 acceptor,	 causing	 it	 too,	 to	 fluoresce.	 	 An	 initial	 image	 is	 taken	
providing	a	reading	of	both	donor	and	acceptor	 fluorescence.	Next,	a	region	of	
interest	(ROI)	is	selected,	and	within	this	ROI,	the	acceptor	is	bleached	out	using	
a	 high-intensity	 laser.	 The	 image	 is	 recaptured	 and	 the	 FRET	 efficiency	 is	
calculated.	 	 	 Upon	 bleaching	 the	 acceptor	 fluorophore,	 the	 donor,	 gives	 off	
higher	 intensity	 fluorescence	when	 excited,	 as	 it	 is	 no	 longer	 sharing	 photons	
with	 the	 acceptor.	 	 Thus,	 if	 there	 is	 a	 direct	 interaction	 between	 donor	 and	
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acceptor,	when	 the	 acceptor	 is	 bleached	 the	 donor	 produces	 a	 brighter	 signal	
than	in	the	pre-bleach	reading.	
To	 determine	 whether	 FRET	 photobleaching	 was	 a	 feasible	 assay	 to	 monitor	
potential	 KpnB1-INI43	 interactions,	 the	 excitation	 and	 emission	 scan	 of	 INI-43	
was	 read	 in	 a	 fluorometer	 and	 compared	 to	 that	 of	 the	 spectra	 of	 FRFP	 in	
pmKate-2c	 (Figure	2.11	A).	 The	 spectra	of	 INI-43	were	also	 read	 inside	 cells	 to	






experiments	 post	 treatment	with	 INI-43.	 	 HeLa	 cells	 grown	 on	 glass	 coverslips	
were	transfected	with	FRFP-KpnB1.		The	cells	were	treated	with	5	µM	INI-43	for	















30-minute	 and	 45-minute	 INI-43-treated	 cells,	 and	 individual	 FRET	
photobleaching	was	performed.	The	average	FRET	efficiency	was	calculated	to	be	
28.13	 for	 the	 30	 min	 treatment	 and	 33.37	 for	 the	 45	 treatment	 which	 was	
significantly	higher	that	the	fret	efficiency	of	the	unbleached	region.		
Analysis	 for	 30-minute	 INI-43	 treated	 cells,	 and	 four	 individual	 FRET	
photobleaching	analyses	for	45-minute	INI-43	treated	cells,	show	comparatively	






































































































Figure	 2.12:	 FRET	 photobleach	 experiments	 showing	 co-localisation	 between	
INI-43	 and	 FRFP-KpnB1.	 (A)	 FRET	 photobleaching	 20	 minutes	 post	 treatment	
with	INI-43.		(B)	FRET	photobleaching	30	minutes	post	treatment	with	INI-43.		(C)	





Table	 2.1:	 Summary	 of	 Results	 shows	 possible	 interaction	 between	 pmKate-























Figure	 2.13	pmKate-2c	 only	 is	 able	 to	 undergo	photo	 conversion	 from	 red	 to	
green.	 	Control	cells	were	transfected	with	pmKate-2c	(no	drug	treatment)	and	
observed	 post	 bleaching.	 Green	 line	 represents	 photo-conversion	 after	




In	 our	 laboratory	 we	 have	 generated	 evidence	 showing	 that	 KpnB1	 is	
upregulated	and	required	for	the	survival	of	cervical	cancer	cells	(van	der	Watt	et	
al.,	2009,	2011;	Angus	et	al.,	2014).		Small	molecule	inhibitors	targeted	to	bind	to	
and	 inhibit	 KpnB1	 is	 therefore	 one	 of	 our	 major	 areas	 of	 interest.	 The	 study	






and	 IC50	of	22.5	μM	 in	HeLa	cells	 (Jonathan	F	Soderholm	et	al.	2011).	 	We	also	
show	that	INI-43	initiates	cell	death	by	activating	apoptotic	pathways.		This	was	
observed	using	the	PARP-1	cleavage	assay.	 	This	result	has	been	 independently	
confirmed	by	others	 in	our	 laboratory	using	PARP-1	 cleavage	 and	other	 assays	
such	as	caspase	3/7	assay	(van	der	Watt	et	al.,	2016).		PARP-1	is	downstream	of	
caspase	3/7	which	activates	the	cleavage	of	PARP-1	on	upstream	signals	from	the	









with	 nuclear	 import	 pathways.	 We	 report	 a	 significant	 decrease	 in	 NFAT	
promoter	activity	in	the	presence	of	INI-43.		NFAT	is	a	transcription	factor,	which	








distinct	 difference	 in	 KpnB1	 localisation	 in	 INI-43-treated	 cells	 compared	 to	
control	 cells,	where	 a	decrease	 in	nuclear	 localisation	was	observed	 in	 treated	
cells.	In	INI-43-treated	cells,	KpnB1	was	localised	in	the	cytoplasm	and	also	to	the	
peri-nuclear	 region	where	 it	 localizes	 in	 high	 concentrations.	 The	 fact	 that	 the	
presence	 of	 INI-43	 interferes	 with	 KpnB1	 localisation	 to	 the	 nucleus,	 suggests	
that	 KpnB1-associated	 nuclear	 import	 will	 be	 inhibited.	 It	 is	 unclear	 whether	
KpnB1	is	remaining	on	the	periphery	of	the	nucleus	or	if	it	is	becoming	trapped	in	
the	endoplasmic	reticulum.	The	only	way	to	be	of	the	location	of	the	drug	would	









with	 INI-43	we	 observed	 an	 exclusion	 of	 FRFP-KpnB1	 from	 the	 nuclear	 region,	
with	localisation	to	the	peri-nuclear	region	becoming	more	prominent.	This	was	
observed	within	30	minutes	of	treatment	with	the	drug.	As	INI-43	is	a	drug	that	
exhibits	 fluorescence,	 we	 were	 also	 able	 to	 show	 changes	 in	 FRFP-KpnB1	
localisation	coincided	with	drug	presence	in	the	cells.		If	INI-43	is	binding	to	the	
region	 of	 interest,	 it	 could	 be	 causing	 re-localisation	 of	 KpnB1	 by	 possibly	
preventing	the	Ran	interaction,	similar	to	the	function	of	importazole	(Jonathan	
F.	 Soderholm	et	al.	2011).	 	 This	deprives	 the	 system	of	 cellular	energy	and	 the	
import	 process	 is	 no	 longer	 able	 to	 occur.	 Another	 possibility	 is	 that	 INI-43	 is	
preventing	the	recognition	and	binding	of	KpnA2.		Such	inhibition	would	prevent	
KpnB1	from	entering	the	nucleus	causing	KpnB1	to	remain	stuck	in	the	cytoplasm	





FRET	 efficiencies,	 the	 final	 result	 was	 inconclusive.	 	 When	 we	 performed	 the	
control	using	cells	expressing	the	empty	vector	pmKate-2c,	we	observed	changes	
in	 fluorescent	 emission	 from	 red	 to	 green.	 Furthermore,	 pmKate-2c	 is	 one	 of	
only	 eight	 known	 fluorescent	 labels	 shown	 to	 change	 emission	 spectra	 on	
photobleaching	 (Kremers	 et	 al.	 2009).	 	 To	 further	 investigate	 potential	 INI-43	
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Previous	 studies	 have	 shown	 that	 KpnB1	 is	 able	 to	 maintain	 the	 intracellular	





silico	 approach	 to	 identify	 small	 molecules	 with	 potential	 to	 bind	 and	 inhibit	
KpnB1	function,	we	identified	INI-43.	
In	 this	 study	and	 in	our	 recently	published	work	 (van	der	Watt	et	al.	2016)	we	
showed	 that	 INI-43	 exerts	 its	 cytotoxic	 effects	 by	 targeting	 KpnB1-associated	
nuclear	 transport	 pathways.	 This	 chapter	 describes	 the	 procedure	 we	 used	 to	
generate	 purified	 KpnB1	 for	 use	 in	 biophysical	 investigation	 of	 protein–drug	
interactions.	 More	 specifically	 we	 required	 purified	 KpnB1	 for	 investigating	
whether	 INI-43	can	 interact	directly	with	KpnB1.	 	Methods	of	purification	used	
included	affinity	chromatography	and	anion	exchange	chromatography.		Affinity	




2006).	 	 	 In	these	purification	methods	the	tagged	protein	becomes	immobilized	





native	 charge	 of	 the	 protein	 to	 purify	 it.	 	 Columns	 have	 size	 exclusion	 and	 a	
positively	charged	resin	that	enables	the	protein	of	interest	to	be	immobilised	by	
the	 resin	 due	 to	 the	 difference	 in	 charge.	 Cellular	 debris	 can	 be	 removed	 by	
washing,	and	a	salt	gradient	is	used	to	elute	the	protein	from	the	resin;	fractions	
are	collected	and	analysed	for	protein	content	using	SDS-PAGE	and	western	blot	
analysis.	 	This	method	requires	knowledge	about	 the	protein’s	 isoelectric	point	
and	 optimal	 pH.	 	 It	 also	 involves	 a	 number	 of	 different	 steps,	 including	 a	 gel	
filtration	for	a	final	stage	of	purification	based	on	size	exclusion.				






become	 attached.	 Once	 the	 protein	 of	 interest	 becomes	 bound	 the	 resin	
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impurities	 can	 be	 removed	 using	wash	 buffers,	 leaving	 the	 pure	 protein	 to	 be	
collected	with	the	imidazole	elution	buffer	(Rosano	&	Ceccarelli	2014).	
















A	 His-tagged	 vector	 system	 (pET-28b+,	 kindly	 donated	 by	 Prof	 Sewell,	 UCT	
Structural	 Biology	 Unit)	 was	 initially	 used	 as	 a	 system	 to	 generate	 KpnB1	 for	
purification.	 	 The	 human	 variant	 of	 KpnB1	 was	 amplified	 by	 PCR	 from	 pGEX-
61	
KpnB1	plasmid	(see	Appendix,	Figure	2).	 	Two	sets	of	primers	were	constructed	
that	 allowed	 for	 one	 clone	with	 an	N-terminal	 His-tag	 and	 a	 second	with	 a	 C-
terminal	 His-tag.	 The	 amplified	 PCR	 products	 were	 run	 on	 a	 1%	 agarose	 gel	
(Figure	3.1	A).			These	inserts	were	A-tailed,	then	cloned	into	the	final	vector	pET-
28b+	via	the	shuttle	plasmid	pGEM-T-EASY.		Restriction	enzyme	digest	was	used	
to	 release	 the	 KpnB1	 insert	 from	 pGEM-T-EASY,	 which	 was	 then	 cloned	 into	
pET28b+,	allowing	for	N-	and	C-terminal	His	tagging.	 	The	 inserts	were	mapped	




E. Coli	BL21	 (DE3)	containing	 the	plasmid	pET28b-KpnB1	encoding	either	C-His-	
or	 N-His-tagged	 KpnB1	 was	 grown	 and	 cultures	 were	 stimulated	 with	 IPTG	 to	
induce	 protein	 production.	 Protein	 lysates	 were	 then	 applied	 to	 affinity	
chromatography	resin.		
Both	N-His-	and	C-His-tagged	variants	of	KpnB1	had	a	 low	affinity	for	the	 IMAC	
resin.	 	 In	 an	 attempt	 to	 increase	 binding,	 the	 flow-through	was	 re-run	 on	 the	





The	binding	 traces	observed	 in	 Figure	3.2	A	 and	B	 clearly	 show	 that	 there	 is	 a	
large	amount	of	protein	in	the	flow-through	(first	peak)	and	then	very	little	in	the	
elution	(second	peak).	Figure	3.2	A,	shows	the	purification	profile	for	the	C-His-
KpnB1	 and	 Figure	 3.2	 B,	 for	 N-His-KpnB1.	 	 The	N-His-KpnB1	 did	 not	 show	 any	
protein	being	 eluted	off	 the	 column	and	 the	C-His-KpnB1	 showed	a	 very	 small	
amount	 of	 protein	 being	 eluted	 off	 in	 the	 form	 of	 the	 second	 peak	 between	
fractions	 25	 and	 27.	 	 Since	 the	 His	 affinity	 tag	 chromatography	 proved	 to	 be	



























2.5	kb	 insert	of	C-His	 tagged	KpnB1	using	 restriction	enzymes	BamHI	and	NotI.	


























































































purification	 for	 both	 N-	 and	 C-terminal	 HIS-KpnB1:	 Lysates	were	 loaded	 onto	
the	column	and	the	protein	concentration	was	measured	using	spectral	analysis	
at	 280nm	 throughout	 the	 process	 to	measure	 the	 efficiency	 of	 the	 technique.	
The	 X-axis	 represents	 time	 and	 fraction	 number	 collected,	 while	 the	 Y-axis	
displays	 absorbance	 at	 280nm;	 the	 concentration	 of	 the	 elution	 gradient	 is	
represented	by	the	green	line.	 	(A)	Examination	of	C-terminal	His-tagged	KpnB1	
shows	 that	most	 of	 the	 protein	was	 lost	 in	 the	 flow-through	 (peak	 1),	while	 a	










KpnB1	 protein	 was	 expressed	 using	 E.	 Coli	 BL21	 (DE3)	 cells	 containing	 the	
plasmid	 pET28b-KpnB1	 encoding	 C–His-tagged	 KpnB1.	 Protein	 lysates	 were	
loaded	 onto	 a	 high-resolution	 anion	 exchange	 chromatography	 column.	 After	
collecting	 the	 lysate,	 the	 induction	 and	 solubility	 of	 the	 protein	was	 visualised	
using	 SDS-PAGE	 (Figure	 3.3	 A)	 and	 western	 blot	 using	 anti	 KpnB1	 (rabbit	

















Figure	 3.3:	 Bacteria	 expressing	 the	 pET-KpnB1	 plasmid	 are	 able	 to	 produce	
soluble	 expression	 of	 His-KpnB1	 protein	 and	 demonstrate	 IPTG-dependant	
induction	of	the	protein.	(A)	Samples	of	the	various	stages	of	induction	and	lysis	











































































































































































































































SDS-PAGE	 analysis	 of	 fractions	 after	 anion	 exchange	 purification.	 (B)	
































































































































































































































Western	blot	analysis	on	eluted	 fractions	 identified	bands	 in	 the	97	kDa	region	
(as	expected	for	KpnB1);	however,	multiple	other	bands	were	also	detected	on	
both	 SDS-PAGE	 (Figure	 3.4	 A)	 and	 by	 western	 blots	 for	 KpnB1	 (Figure	 3.4	 B).		




Select	 fractions	 were	 analysed	 using	 western	 blot	 for	 KpnB1	 in	 the	 fraction	
(Figure	3.5).		
In	 total	 two	 rounds	 of	 anion	 exchange	 were	 performed	 and	 following	 anion	




















Figure	 3.5:	Western	 blot	 of	 fractions	 from	 second	 round	 of	 anion	 exchange.		
Selected	 fractions	 from	 the	 second	 round	 of	 anion	 exchange	were	 probed	 for	
KpnB1.		The	blots	show	an	increase	in	the	level	of	enrichment	and	purity	of	His-
KpnB1	around	the	fraction	numbers	34	to	60.	Fractions	were	run	on	3	separate	



































Figure	3.6:	Results	 from	gel	 filtration	 shows	protein	 in	 the	97	 kDa	and	 lower	
molecular	weight	bands	still	present.	(A)	Fractions	from	gel	filtration	most	likely	
to	contain	His-KpnB1	were	analysed	using	SDS-PAGE	showing	fractions	from	gel	
filtration.	 	 (B)	 Fractions	were	 pooled	 and	 re-analysed	 using	 SDS-PAGE	 showing	



























































































































































with	 HeLa	 lysates	 used	 as	 a	 positive	 control	 for	 KpnB1	 in	 western	 blots.		
Surprisingly,	 after	 the	 pooling	 of	 fractions	 and	 performing	 western	 blots	 for	








as	 the	 methods	 tried	 thus	 far	 (His-tag	 affinity	 chromatography	 and	 anion	








































































The	 plasmid	 pIB-GFP,	 containing	 (KpnB1-GFP)	was	 kindly	 provided	 to	 us	 by	M.	
Ciciarello	and	colleagues	 (see	M.	Ciciarello	et	al.,	2004	and	Appendix	Figure	2).		





the	 2.5	kb	 product	 was	 cloned	 into	 pGex-6p1.	 Inserts	 were	 visualised	 using	
restriction	enzyme	digest	with	BamHI	and	XmaI	 (Figure	3.8	B).	 	 	The	 insert	was	
sequence	 confirmed	 and	 pGex-6p1-KpnB1	 transfected	 into	 E.	 Coli	 (JM109)	
bacteria	 cells.	 	 Expression	 of	 GST-tagged	 KpnB1	was	 induced	 using	 IPTG.	 	 Our	
















of	 2.5	kb	 KpnB1	 for	 insertion	 into	 pGEX-6P1.	 (B)	 Visualisation	 of	 2.5	kb	 KpnB1	
insert	excised	 from	the	plasmid	using	 restriction	enzymes	BamHI	and	XmaI.	 (C)	
Western	blot	for	KpnB1	demonstrating	successful	induction	of	GST-	KpnB1	upon	
stimulation	 with	 IPTG	 over	 1,	 2	 and	 3	 hours.	 	 Un-induced	 lane	 (0	 hr)	 shows	


































































was	 added	 to	 the	 resin,	 the	 mixture	 was	 placed	 on	 a	 rotator	 at	 room	
temperature	for	4	hours	then	moved	to	the	cold	room	(4˚C)	where	it	continued	
to	 rotate	overnight.	 	 Elution	was	performed	using	a	 solution	of	 ice-cold	50mM	
reduced	glutathion	(Sigma)	in	water	pH	7.5	–	8.		




of	 KpnB1	 in	 our	 results	 showed	 the	 GST-tagged	 purification	 methods	 was	
substantially	 improved	 to	 the	 earlier	methods	 attempted.	 	While	minor	 bands	
were	 still	 detected,	 a	 concentration	 of	 protein	 was	 observed	 in	 the	 ~123	 kDa	
region	of	eluted	fractions	(Figure	3.9	A).		This	corresponds	to	the	expected	size	of	
KpnB1	at	97	kDa	fused	to	the	GST-tag	(26	kDa).	
Western	blot	analysis	 showed	KpnB1	cross	 reactivity	at	 the	correct	 size	 (Figure	









Figure	 3.9:	 Purification	 of	 GST-KpnB1	 was	 successful	 using	 glutathione	
sepharose	 resins	 and	 achieved	 a	 desired	 level	 of	 purity.	 (A)	Various	 fractions	
from	batch	binding	were	analysed	by	SDS-PAGE	using	BSA	standard	(μg	BSA).	(B)	
Western	 blot	 to	 showing	 various	 fractions	 from	 batch	 binding.	 (C)	 Mass	



















































































spectrometry	 analysis	 confirming	 its	 purity	 to	 be	 between	 92.5	 and	 77.28%.			
There	 was	 however	 some	 keratin	 contamination	 observed	 in	 the	 mass	
spectrometry	 analysis,	 despite	 having	 all	 precautions	 in	 place	 to	 prevent	
contamination.				
The	 purified	 GST-tagged	 KpnB1	 was	 subsequently	 used	 to	 investigate	 KpnB1–
















Sample	 Intensity	 μg	in	sample	 μg/μL	 Total	protein	 %	Yield	 %	Purity	
Crude	 18361.37	 4.77	 0.48	 9544.86	 100.00	 22.73	
Flow	through	 13393.24	 3.44	 0.69	 13751.37	 144.07	 18.85	
Wash	1	 53847.87	 143.05	 1.43	 14305.15	 149.87	 63.49	
Wash	2	 25045.40	 6.57	 0.66	 6567.96	 68.81	 43.05	
Elution	1	 78434.87	 15.18	 1.52	 1517.50	 15.90	 38.84	
Elution	2	 35648.32	 4.85	 0.49	 485.09	 5.08	 42.07	














this	 IBB	 domain	 was	 co-crystalized	 bound	 together,	 hence	 once	 KpnB1	 was	
immobilized	 to	 the	 KpnA2	 column	 it	 was	 unnecessary	 to	 separate	 the	 binding	




binding	 analysis,	 and	 separating	 KpnB1	 from	 the	 IBB	 domain	 may	 have	 been	
problematic.	We	therefore	chose	to	use	simpler	purification	methods.			













time-consuming	 steps	 involved	 in	 anion	 exchange	 purification,	 protein	
degradation	 was	 observed,	 which	meant	 that	 this	 technique	 failed	 to	 provide	
optimal	results	for	the	purification	of	KpnB1.		
Our	 biggest	 challenge	 with	 the	 purification	 of	 KpnB1	 was	 to	 obtain	 large	
quantities	 (μg	 amounts)	 of	 sufficiently	 pure	 protein	without	 degradation.	 	 The	
use	 of	 GST-affinity	 tag	 purification	methods	 enabled	 us	 to	 overcome	 some	 of	
these	challenges.	GST-affinity	tag	purification	is	a	single-step	purification	system	
and	 therefore	 more	 suitable	 for	 the	 purification	 of	 KpnB1,	 thus	 suiting	 our	
requirements.	
The	 mass	 spectrometry	 results	 we	 achieved	 revealed	 that	 the	 purified	 KpnB1	
was	sufficiently	pure	(~95%)	suggesting	it	was	of	a	quality	that	could	be	used	in	
the	biophysical	analysis	 to	examine	drug–protein	 interactions	as	 recommended	
by	 (Pihan	 et	 al.	 2015).	 Purified	 KpnB1	was	 used	 to	 assess	whether	 INI-43	was	







Purified	 KpnB1	was	 used	 to	 perform	 biophysical	 analyses	 in	 order	 to	 examine	
structural	 interactions	 between	 KpnB1	 and	 INI-43.	 	 We	 used	 two	 methods	 of	
analysis,	circular	dichroism	(CD)	and	isothermal	calorimetry	(ITC).		CD	is	a	form	of	
spectroscopy	which	makes	use	of	 the	differential	 absorption	of	 left-	 and	 right-
circularly	 polarised	 light	 (Rogers	 &	 Hirst	 2004;	 Kelly	 &	 Price	 2006).	 	 Linearly	
polarized	 light	 is	 observed	 when	 light	 travels	 in	 an	 oscillating	 electromagnetic	
wave	 with	 constant	 amplitude.	 Circularly	 polarised	 light	 is	 created	 when	 two	
waves	of	linear	polarised	light	of	equal	amplitude	are	combined	at	90°	opposing	
phases	to	each	other	(Figure	4.1)	(Rogers	&	Hirst	2004).		The	radiation	generated	
by	 this	 light	 is	 used	 to	 produce	 a	 CD	 signal	 commonly	measured	 in	 ellipticity.		
Optically	 active	 amino	 acids	 make	 it	 possible	 to	 use	 CD	 to	 measure	 the	
transitions	 of	 electrons	 within	 proteins	 to	 different	 levels	 of	 the	 excited	 state	
(Rogers	&	Hirst	2004).	This	method	utilises	a	 range	of	wavelengths	 to	measure	
ellipticity	 of	 the	 protein	 being	 examined	 (Kelly	 et	 al.	 2005)	 (Figure	 4.1).	 A	
signature	 reading	 in	 terms	 of	 ellipticity	 can	 be	 deciphered	 (Greenfield	 2006c)	
which	 gives	 insight	 into	 secondary	 structure	 (Kelly	 et	 al.	 2005).	 	 Typically,	 CD	
spectra	between	180nm	and	260nm	can	be	examined	to	analyse	the	secondary	
structure	 of	 a	 protein	 under	 investigation	 (Greenfield,	 2006c).	 	 Secondary	
structures	 such	 as	 alpha	 helices,	 beta	 sheets,	 turns	 and	 random	 coils	 provide	




protein	 chromophores	 –	 peptide	 bonds,	 amino	 acid	 side	 chains	 and	 the	





Figure	 4.1:	 Circularly	 polarised	 light	 used	 in	 CD.	 (A)	 Linearly	 polarised	 light	 is	
produced	by	waves	of	 constant	 amplitude.	 (B)	 Two	waves	of	 linearly	 polarised	
light	in	transverse	planes	of	equal	amplitude	at	opposing	90°	phases	are	used	to	
produce	circularly	polarised	light.		(C)	Circularly	polarized	light	can	be	left-circular	
or	 right-circular;	 both	 are	 used	 in	 CD	 analysis	 (From	 http://hyperphysics.phy-
astr.gsu.edu/hbase/phyopt/polclas.html).	
Factors	which	can	influence	the	CD	spectra	of	aromatic	amino	acids	include	the	
rigidity	 of	 the	 protein	 and	 the	 presence	 of	 hydrogen	 bonds	 (Kelly	 et	 al.	 2005;	
Rogers	&	Hirst	2004).		As	mentioned,	secondary	structures	within	a	protein	have	








seen	 by	 line	 number	 2	 in	 Figure	 4.2.	 	 Disordered	 proteins	 have	 no	 distinct	
spectral	pattern	as	seen	by	and	as	seen	by	line	number	5	in	Figure	4.2.	
Examining	 the	 response	 of	 CD	 spectra	 under	 the	 influence	 of	 increasing	 heat	












Figure	 4.2	 Secondary	 structures	 produce	 characteristic	 spectra.	The	excitation	
of	 various	 electrons	 on	 specific	 orbitals	 causes	 each	 secondary	 structure	 to	
produce	a	characteristic	spectrum,	thus	making	it	possible	to	examine	changes	in	
secondary	structure	(Greenfield	2006c).	




binding	 (Greenfield	 2006a).	 	 Similarly,	 it	 is	 possible	 to	 examine	 changes	within	
the	spectra	in	response	to	the	addition	of	ligands,	and	thereby	explore	the	effect	
of	 small	 molecules	 on	 protein	 folding	 and	 the	 binding	 affinity	 of	 the	 small	
molecules.	 	 CD	 cannot,	 in	 most	 cases,	 provide	 specific	 molecular	 information	
regarding	protein	ligand	binding	at	an	atomic	level,	and	it	is	therefore	employed	
in	conjunction	with	other	techniques	such	as	 ITC,	NMR	or	X-ray	crystallography	
(Rogers	 &	 Hirst	 2004).	 	 It	 does,	 however,	 provide	 an	 indication	 of	 structural	
change	and	makes	it	possible	to	obtain	a	preliminary	disassociation	constant	(Kd).	
This,	 in	 turn,	 provides	 insight	 into	 the	 affinity	 of	 the	 ligand	 (or	 drug)	 for	 the	
protein	(Kelly	&	Price	2006;	Kelly	et	al.	2005).		
In	 addition	 to	 CD	 as	 a	 measure	 of	 drug–protein	 interaction,	 we	 used	 ITC	 to	
measure	 the	 thermodynamics	 of	 the	 binding	 interactions	 between	 KpnB1	 and	
INI-43.	 Successful	 interaction	 between	 a	 drug	molecule	 and	 the	 target	 protein	
requires	 the	 formation	 of	 non-covalent	 bonds	 (Holdgate	 &	 Ward	 2005a).			
Formation	 of	 these	 bonds	 is	 regulated	 by	 the	 affinity	 of	 the	 ligand	 for	 the	
respective	protein,	and	the	production	of	these	bonds	can	be	measured	by	using	
isothermal	calorimetry	(ITC).	 	This	thermodynamic	technique	 is	regarded	as	the	
gold	 standard	 in	measurement	 of	 drug–protein	 interactions	 and	 generation	 of	
data	on	binding.				
The	 ITC	apparatus	measures	 the	changes	 in	 temperature	or	enthalpy	 (ΔH)	 that	
accompany	 molecular	 binding	 interactions	 (Holdgate	 &	Ward	 2005a),	 and	 the	




The	 ITC	 apparatus	 is	 a	 closed	 system	 in	which	 differential	 feedback	 is	 used	 to	
measure	and	determine	the	precise,	minute	temperature	changes	that	 indicate	
the	 occurrence	 of	 drug	 binding.	 	 The	 apparatus	maintains	 a	 constant	 baseline	
temperature,	 and	 should	 the	 closed	 system	 temperature	 shift	 due	 to	 the	
energetics	of	drug	binding	the	system	immediately	corrects	itself	via	comparison	
with	 a	 reference	 cell.	 	 ITC’s	 quantification	 of	 change	 from	 a	 baseline	 value	
provides	 valuable	 insight	 into	 the	 thermodynamics	 of	 drug	 binding	 when	 3-D	
binding	 data	 is	 not	 available.	 	 The	 information	 provided	 by	 ITC	 includes	 the	
binding	constant	(Ka)	and	its	dissociation	constant	(Kd),	which	together	give	key	












ΔG = −RTlnK! = ∆H°− T∆S°	 (Holdgate	&	Ward	2005b)	




	The	 free	 energy	 represented	 by	 ΔG	 is	 a	 measure	 of	 how	 spontaneously	 a	
reaction	takes	place.	The	more	negative	 this	 factor	 is,	 the	more	 favourable	 the	




in	negative	enthalpy.	The	more	negative	 the	value	of	ΔH,	 the	more	 favourable	
the	 binding	 reaction	 (i.e.	 the	 more	 bonds	 formed).	 This	 value	 provides	
information	 relating	 to	 the	 possible	 formation	of	 hydrogen	bonds	 and	 van	der	
Waals	 interactions.	 It	 must	 however	 be	 taken	 into	 account	 that	 solvents	 and	
buffers	 can	 affect	 this	 value;	 the	 ideal	 is	 therefore	 it	 is	 ideal	 to	 have	 3D	
crystallographic	 data	 if	 a	 completely	 accurate	 measure	 of	 binding	 is	 required	
(Ladbury	2010;	Holdgate	&	Ward	2005a).	
Entropic	 information	 on	 the	 drug	 interaction	 is	 represented	 by	 the	 ΔS	 value	










−TΔS = ∆G− ∆H	 (Holdgate	&	Ward	2005b)
Equation	 4.3:	 Measurement	 of	 hydrophobic	 interactions	 is	 calculated	
experimentally.	 Once	 the	 parameters	 ΔG	 and	 ΔH	 have	 been	 calculated	 by	
experimentation	they	can	be	used	to	solve	the	equation	for		–TΔS.			
This	chapter	describes	our	use	of	purified	protein	for	biophysical	analysis	with	CD	
and	 ITC,	 prompted	 by	 in-vitro	 data	 (Chapter	 2),	 which	 suggests	 that	 INI-43	
inhibits	 nuclear	 membrane	 transport	 of	 KpnB1.	 Biophysical	 techniques,	 were	




Having	 established	 that	 GST	 purification	 methods	 enrich	 for	 GST-KpnB1,	 this	
purified	protein	was	used	in	CD	experiments.	Using	a	final	protein	concentration	
of	 0.2mg/mL	 for	 GST-KpnB1,	 a	 spectral	 analysis	 of	 KpnB1	was	 obtained	 in	 the	




Initial	 experiments	were	 performed	with	 INI-43	 solubilised	 in	 DMSO.	 However	
we	 found,	 that	 DMSO	 absorbs	 strongly	 within	 the	 280nm	 range,	 causing	
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appears	 to	 be	 rich	 in	 alpha	 helices,	 evident	 from	 the	 positive	 band	 at	 190nm	
value	and	negative	bands	at	233	and	240nm.		
On	 addition	 of	 INI-43,	 there	 is	 a	 distinct	 rightward	 and	 upward	 shift	 in	 the	
spectra	observed	(Figure	4.3).		This	shift	was	strongly	evident	around	the	233nm	
region.	Spectral	shifts	within	this	wavelength	have	previously	been	attributed	to	
possible	 interactions	 in	 a	 region	 of	 the	 protein	 containing	 numerous	 aromatic	
amino	acids	(Rogers	&	Hirst	2004;	Greenfield	2006a).		
There	 was	 a	 rapid	 saturation	 of	 binding,	 which	 was	 an	 indicator	 that	 lower	
concentrations	of	INI-43	were	required	for	a	better	titration.	INI-43	appeared	to	
have	 quenched	 KpnB1	 rapidly,	 thereafter	 dominating	 the	 reading.	 	Our	 results	
provide	 evidence	 that	 INI-43	 binds	 to	 a	 region	 rich	 in	 aromatic	 amino	 acids	
(present	in	the	region	where	INI-43	was	designed	to	bind)	but	because	aromatic	
amino	 acids	 are	 distributed	 throughout	 KpnB1	 we	 cannot	 definitely	 conclude	
that	 INI-43	 binds	 within	 the	 region	 of	 HEAT	 repeats	 5	 and	 6.	 Structural	 data	
would	be	required	to	verify	this	observation.		Figure	4.4	shows	where	all	of	these	






(Wiedemann	 et	 al.	 2013)	 to	 examine	 the	 secondary	 structure	 of	 the	 purified	






how	 much	 data	 other	 users	 have	 already	 loaded	 into	 the	 program	 and	 how	
similar	 it	 is	 to	 the	 current	user’s	data.	 	 In	addition,	 the	absence	of	CD	 spectral	
data	 for	 KpnB1	 with	 which	 we	 could	 compare	 our	 results	 means	 that	 the	
program	 as	 used	 in	 our	 study	 must	 be	 taken	 as	 a	 guide	 rather	 than	 as	 an	
absolute	measure.		Figure	4.5	A	is	the	program	estimate	of	how	the	CD	spectra	
should	 look	 based	 on	 the	 amino	 acid	 sequence	 and	 loaded	 spectral	 data	 from	
Figure	 4.3.	 	 Figure	 4.5	 B	 is	 the	 how	 the	 program	 interprets	 the	 secondary	
structure	 of	 the	 protein,	 red	 is	 alpha	 helix,	 green	 is	 beta	 sheet	 and	 black	 is	
irregular.		This	is	based	on	the	amino	acid	sequence	and	shows	99%	alpha	helix	









this	 data	 does	 show,	 is	 that	 the	 purified	 KpnB1	 is	 rich	 in	 alpha	 helices,	 which	
suggests	the	structure	of	the	protein	is	intact.		Figure	4.5	C	is	proteins	already	in	






















drug	 with	 the	 protein.	 INI-43	 was	 titrated	 into	 purified	 KpnB1	 enabling	 the	
elliptical	data	to	be	examined	over	a	range	of	wavelengths,	scanning	from	180nm	
























Figure	 4.5:	 Predicted	 secondary	 structural	 content	 of	 purified	 GST-KpnB1.		
Spectral	 data	 was	 loaded	 into	 a	 webserver-based	 analytical	 tool	 to	 analyse	
secondary	 structural	 content.	 	 In	 relation	 to	 differences	 from	 the	 predicted	
structure,	allowance	must	be	made	 for	a	degree	of	 inaccuracy	 in	 the	software.	
(Wiedemann,	 Bellstedt,	 &	 Gorlach,	 2013)	 (A)	 Shows	 the	 predicted	 CD	 spectral	



















titrations	 performed	 were	 as	 accurate	 as	 possible	 (Figure	 4.6	 A).	 	 The	 figure	
shows	that	at	the	four	selected	wavelengths,	there	is	an	overall	linear	change	in	
the	 spectra	as	 the	 concentration	of	 INI-43	 is	 increased.	 	 This	data	was	used	 to	
standerdise	the	raw	data.		Overall	insight	into	the	binding	interactions	of	KpnB1	















Figure	 4.6:	 Spectral	 analysis	 of	 INI-43	 titration	 shows	 possible	 secondary	
structural	 change	of	KpnB1	upon	binding	 to	 INI-43:	Graphs	show	ellipticity	vs	
ligand	concentration	at	predetermined	wavelengths.	(A)	Spectral	analysis	of	INI-
43	at	wavelengths	of	190-233	nm.	(B)	Examination	of	KpnB1	and	KpnB1	with	INI-
43	 vs.	 INI-43	 at	 the	maxima	 190nm	 shows	 change	 in	 secondary	 structure	 and	
interaction	 between	 INI-43	 and	 KpnB1.	 	 (C)	 Examination	 of	 KpnB1	 and	 KpnB1	
with	 INI-43	 vs.	 INI-43	 210nm	 shows	 change	 in	 secondary	 structure	 and	



















At	 190nm,	 an	 inverse	 relationship	 between	 the	 ellipticity	 of	 INI-43	 and	 KpnB1	
was	 observed	 as	 increasing	 concentrations	 of	 INI-43	 was	 titrated	 into	 the	







To	 further	 visualise	 the	 possible	 INI-43-KpnB1	 interaction,	 the	 original	 binding	
data	(Figure	4.3)	was	used	to	generate	binding	isotherms	using	GraphPad	Prism	
software.		We	examined	three	different	wavelengths	–	190nm,	208nm	(another	
region	 where	 secondary	 structural	 changes	 are	 observed)	 and	 210nm.	 From	
these	 binding	 isotherms	 we	 were	 able	 to	 obtain	 a	 Bmax	 and	 Kd	 to	 aid	 in	 the	
setup	of	 the	 ITC	experiments.	 	Bmax	 is	a	measure	of	 the	maximum	quantity	of	
binding	 sites	 occupied,	while	 Kd	 is	 the	 disassociation	 constant	 and	measure	 of	
affinity.	The	isotherm	data	suggested	that	INI-43	binds	to	KpnB1	with	an	affinity	










Saturation Binding Data: 208nm
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Saturation Binding Data: 190nm
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Saturation Binding Data: 210nm
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ITC	 experiments	 were	 performed	 using	 a	 MicroCal™	 iTC200	 (GE	 Healthcare)	 at	
24°C	with	 purified	 GST-	 KpnB1	 in	 50mM	Hepps	 buffer	 and	 8.5%	 DMSO	 in	 the	
sample	cell,	and	INI-43	in	50mM	Hepps	buffer	and	8.5%	DMSO	was	titrated	into	
the	chamber	via	 the	syringe	with	constant	mixing.	 	We	used	Hepps	as	 it	had	a	
low	heat	of	ionisation	and	allowed	us	to	provide	a	pH	of	8,	and	DMSO	was	used	
to	 balance	 out	 the	 solvent	 in	 the	 syringe.	 	 DMSO	 has	 a	 very	 high	 heat	 of	
ionisation,	and	if	the	cell	and	the	syringe	are	not	balanced,	the	heat	of	ionisation	
will	mask	any	heat	of	binding.		This	experiment	was	repeated	in	triplicate	and	at	
three	 separate	 intervals.	 Data	 analysis	 was	 performed	 using	 Origin	 7	 software	
(MicroCal,	USA).		





is	 injected	 into	 the	 cell	 containing	 KpnB1	 the	 ITC	 apparatus	 measures	 the	
temperature.	 	Heat	 released	as	 the	drug	binds	 it	visualised	by	 the	peaks	 in	 the	
raw	data.	 	 The	 raw	data	 is	 converted	 into	a	binding	 isotherm	by	 the	 software,	
which	then	produces	important	binding	data	(Figures	4.8-4.10)	as	represented	in	
figures,	the	protein	saturates	rapidly	and	only	the	top	of	the	binding	curve	can	be	




INI-43	with	50	μM	KpnB1	protein.	Upper	 graph	 represents	 the	 raw	 ITC	data	 in	
which	 the	 incremental	 heat	 changes	 are	 shown	 as	 microcalories	 per	 second	
plotted	against	time	in	minutes	over	the	progression	of	the	experiment.	 	Lower	

















Figure	4.10:	 ITC	data	 for	 INI-43	with	KpnB1.	Repeat	of	binding	data	generated	
750	μM	INI-43	with	50	μM	KpnB1	protein.	Upper	graph	represents	the	raw	ITC	
data	 in	 which	 the	 incremental	 heat	 changes	 are	 shown	 as	 microcalories	 per	
second	plotted	against	time	in	minutes	over	the	progression	of	the	experiment.		
Lower	 graph	 shows	 the	 normalised	 integration	 data	 in	 terms	 of	 kcal.mol-1	 of	
injectant	plotted	against	the	molar	ratio	of	the	added	titrant	with	the	curve	fitted	
to	 single	 site	model.	 The	 two	 axes	 are	 linked,	 allowing	 the	 interacted	 area	 for	
each	peak	to	be	positioned	directly	below	the	associated	peak	 in	the	raw	data.	
The	 negative	 peaks	 correspond	 to	 addition	 of	 an	 aliquot	 of	 ligand.	 	 The	





the	 incremental	 heat	 changes	 are	 shown	 as	 microcalories	 per	 second	 plotted	
against	 time	 in	minutes	 over	 the	progression	of	 the	 experiment.	 	 Lower	 graph	
shows	the	normalised	integration	data	in	terms	of	kcal.mol-1	of	injectant	plotted	
against	 the	molar	 ratio	of	 the	added	 titrant	with	 the	 curve	 fitted	 to	 single	 site	
model.	The	two	axes	are	linked,	allowing	the	interacted	area	for	each	peak	to	be	
positioned	 directly	 below	 the	 associated	 peak	 in	 the	 raw	 data.	 The	 negative	






In	 the	 initial	 ITC	experiments,	we	used	a	relatively	high	concentration	of	 INI-43	
(750	μM)	and	KpnB1	(50	μM)	and	saw	the	drug	saturating	the	protein	too	quickly	
(Figures	4.8	&	4.9),	preventing	the	generation	of	a	complete	binding	curve.		ITC	
experiments	 wee	 also	 performed	 using	 250	 μM	 INI-43	 and	 50	 μM	 KpnB1	 and	
binding	 curves	 shown	 in	 Figure	 4.10	 as	 with	 the	 higher	 drug	 concentrations,	
optimal	 binding	 data	 was	 not	 obtained.	 	We	 did	 however	 use	 this	 data	 in	 an	
attempt	to	generate	thermodynamic	data.	
Using	 the	data	 collected	 from	 ITC	 (Figures	4.8-1.10)	 and	 the	equations	4.1-4.3,	
Table	 4.1	 was	 constructed	 to	 summarise	 the	 results	 and	 important	
thermodynamic	data.		Based	on	the	table	it	is	clear	that	the	results	vary	between	
the	experiments	as	we	were	unable	to	acquire	complete	binding	data	for	INI-43	
with	KpnB1.	Of	particular	 interest	 is	 the	number	of	binding	sites	 is	 less	 than	1,	
this	being	an	indicator	of	INI-43	having	a	low	affinity	for	KpnB1	and	can	result	in	
incomplete	 binding	 data.	 	 The	 Kd	 values	 obtained	 from	 ITC	 were	 higher	 than	
those	obtained	using	CD	analysis	which	predicted	a	Kd	value	 range	of	between	















ΔG°	 -T	ΔS° N	(Sites)	 Kd	(Mol	-1)	
0.05mM	 0.75mM	 -1.267×106	 -4.23x103 -2.573×104	 1.267×106	 0.045 0.299	
0.05mM	 0.75mM	 -8.283×105	 -2.76x103 -2.216×104	 8.061×105	 0.081 1.272×10-4	






Initial	 analysis	 of	 INI-43	 and	 KpnB1	 interactions	 was	 performed	 using	 CD	 to	
measure	 drug–protein	 interactions.	 The	 advantage	 in	 adopting	 this	 technique	
was	 that	 it	 required	minimal	 amounts	 of	 purified	 protein	 to	 potentially	 detect	
the	effects	of	INI-43	on	KpnB1.		In	performing	this	CD	analysis	we	titrated	INI-43	
into	the	purified	protein	and	determined	the	spectra.		The	purified	KpnB1	on	its	
own	 exhibited	 characteristic	 spectra	 in	 which	 there	 was	 a	 positive	 band	 at	
190nm	and	a	negative	band	between	210	and	220nm,	indicative	of	a	protein	rich	
in	 alpha	 helices	 (Rogers	 &	 Hirst	 2004).	 Although	 circular	 dichroism	 is	 not	 a	
completely	 accurate	 method	 of	 determining	 secondary	 structure	 and	 X-ray	
crystallography	 can	 provide	 precise	 measurements	 of	 key	 aspects	 of	 protein	
secondary	structure	within	the	protein,	the	data	achieved	here	regarding	protein	
structure	 is	 nonetheless	 in	 accordance	 with	 the	 structures	 in	 the	 PDB.	 	 After	
testing	a	range	of	varying	INI-43	concentrations	with	the	purified	protein,	it	was	
clear	 that	 there	was	 a	 binding	 interaction	between	KpnB1	 and	 INI-43,	 possibly	
within	 the	 region	 rich	 in	 aromatic	 amino	 acids.	 	 This	 was	 concluded	 from	 the	
observed	shift	in	the	spectra,	which	occurred	specifically	in	the	233nm	region.	It	
is	also	possible	that	INI-43	binding	causes	changes	to	the	secondary	structure	of	
the	 protein.	 	 Energy	 transitions	 within	 a	 peptide	 chromaphore	 leads	 to	 an	
excitation	 of	 electron	 orbitals	 observed	 between	 the	 regions	 of	 190nm	 and	







wavelength	provide	 information	on	modifications	 in	 secondary	 structure	 in	 the	
protein	 under	 review	 (Rogers	 &	 Hirst	 2004;	 Greenfield	 2006c).	 	 Aromatic	
residues,	 can	 have	 a	 significant	 effect	 on	 the	 CD	 spectra	 in	 the	 230nm	 region	
(Rogers	&	Hirst	2004);	we	therefore	included	this	region	in	our	observations.	





data.	 	 The	 data	 gathered	 through	 this	 technique	 showed	 that	 although	 INI-43	





is	 able	 to	 dimerise	which	 could	mask	 the	 binding	 site	 for	 INI-43	 (Fabrini	 et	 al.	
2009).	 	 GST	 is	 known	 to	 regulate	 apoptotic	 pathways	 in	 cells	 and	 have	 been	
shown	 experimentally	 to	 have	 Kd	 values	 within	 the	 nM	 range	 (Fabrini	 et	 al.	
2009).	 	 Removing	 the	 tag	 or	 using	 alternative	 purification	 methods	 may	 be	 a	
better	approach.	













and	 any	 torsion	 or	 alteration	 of	 the	 protein	 structure	 could	 result	 in	
displacement	of	the	drug	if	the	bonding	is	not	strong	enough.			
While	 the	 ITC	data	 is	 no	 replacement	 for	 a	3-D	 crystallographic	 analysis	of	 the	
integration	 between	 INI-43	 and	 KpnB1,	 we	 can	 conclude	 that	 INI-43	 is	 indeed	
binding	 to	KpnB1,	although	 the	binding	 strength	 is	 low	 in	 terms	of	Kd	and	ΔG°.	
The	 binding	 reaction	 could	 potentially	 be	more	 favourable	 if	modifications	 are	
made	to	the	structure	of	INI-43.		Low	Kd	values	(in	the	μM	range)	were	obtained	
with	the	data	generated	suggested	a	weak	 interaction	between	KpnB1	and	INI-
43.	 Successful	 small	 molecule	 inhibitors	 are	 described	 to	 have	 a	 Kd	 of	
approximately	1x10-9	and	1x10-12,	(Kuriyan	et	al.	2009).	The	Kd	we	obtained	was	












has	 been	 the	 focus	 of	 considerable	 interest	 in	 the	 past	 decade	 (Alifrangis	 &	
McDermott	 2014).	 Literature	 reports	 and	 from	 our	 laboratory	 and	 others,	
reports	that	the	upregulation	of	the	nuclear	transport	family	of	proteins	known	
as	 Karyopherins	 associates	with	 cancer	 (van	 der	Watt	 et	 al.	 2009;	Ward	 et	 al.	
2011;	Gerecitano	2014;	Abdul	Razak	et	al.	2016).		This	study	focuses	specifically	
on	 the	 import	 protein	 KpnB1,	 as	we	have	previously	 shown	 that	 targeting	 this	
protein	 specifically,	 using	 siRNA,	 results	 in	 cervical	 cancer	 cell	 death	 (van	 der	
Watt	 et	 al.	 2009;	 van	 der	Watt	 et	 al.	 2013).	 	 These	 observations	 lead	 to	 the	
hypothesis	 that	 the	 nuclear	 import	 protein	 KpnB1	 is	 necessary	 for	 the	
proliferation	 of	 cancer	 cells	 and	 we	 therefore	 used	 a	 rational	 drug	 design	
approach	 to	 identify	 small	 molecule	 inhibitors	 with	 potential	 to	 bind	 to	 and	
inhibit	KpnB1.			
Using	 the	 known	 crystal	 structure	of	 KpnB1,	 an	 in	 silico	 screen	was	performed	
against	12	662	570	compounds,	searching	for	structures	with	the	ability	to	bind	
KpnB1.	 Our	 laboratory	 tested	 forty-seven	 of	 the	 compounds	 identified	 with	
potential	 to	 bind	 KpnB1,	 using	 in	 vitro	 experiments	 with	 CaSki	 cervical	 cancer	
cells.	 These	 compounds	 were	 tested	 for	 their	 effects	 on	 cell	 death	 and	
proliferation,	 and	 their	 ability	 to	 inhibit	 nuclear	 transport.	 	 Of	 the	 compounds	
tested,	a	compound	referred	to	as	inhibitor	of	nuclear	import	43	(INI-43)	not	only	





shown	 by	 immunofluorescence	 microscopy	 and	 cell	 fractionation	 studies	 (van	
der	 Watt	 et	 al.	 2016).	 Aspects	 of	 our	 research	 presented	 in	 this	 thesis	 were	
included	in	the	van	der	Watt	et	al.,	(2016)	manuscript.	
This	project	was	aimed	at	 investigating	 the	biological	effects	of	 small	molecule	
INI-43	 and	 examining	 its	 ability	 to	 interact	 with	 KpnB1	 via	 drug-protein	
interactions.	 	 During	 In	 vitro	 analysis	 to	 investigate	 the	 effects	 of	 INI-43	 on	
cervical	 cancer	 cells,	 INI-43	 was	 found	 to	 be	 cytotoxic	 with	 an	 IC50	 of	
approximately	10μM	in	both	HeLa	and	CaSki	cervical	cancer	cells.	Further	studies	
into	 the	mode	 of	 cell	 death	 indicated	 that	 INI-43	 treated	 cells	 were	 dying	 via	




increasing	 doses	 of	 INI-43,	 indicating	 inhibition	 of	 nuclear	 import	 of	 the	
transcription	factor	NFAT.	
Using	 immunofluorescent	analysis	and	confocal	microscopy,	we	visualised	both	
endogenous	 and	exogenous	expression	of	 KpnB1	 in	 cervical	 cancer	 cells	 in	 the	
absence	and	presence	of	INI-43.	Endogenously	expressed	KpnB1	showed	altered	
localisation	from	the	nucleus	to	the	cytoplasm	and	a	concentration	of	KpnB1	in	
the	peri-nuclear	 region	 in	 the	presence	of	 INI-43.	 	This	effect	was	 likely	due	 to	
inhibition	of	KpnB1	nuclear	translocation	on	treatment	with	INI-43.		
HeLa	 cells	 expressing	 exogenous	 levels	 of	 far-red	 fluorescently	 tagged	 KpnB1	
(FRFP-KpnB1)	 displayed	 a	 similar	 relocation	 of	 FRFP-KpnB1	 after	 INI-43	
110	
treatment.	 INI-43	was	observed	 to	be	 taken	up	by	 the	cells	within	20	minutes,	
and	 use	 of	 an	 FRFP-KpnB1	 showed	 that	 treatment	 of	 HeLa	 cells	 with	 INI-43	
resulted	in	a	redistribution	of	the	FRFP-KpnB1	from	a	mainly	nuclear	localisation	
to	 the	 peri-nuclear	 region	 of	 the	 cell,	 showing	 a	 peri-nuclear	 FRFP-KpnB1	was	
formed	in	treated	cells.	This	provided	further	evidence	that	INI-43	interferes	with	
the	nuclear	localisation	of	KpnB1.			
Having	 achieved	 conclusive	 data	 that	 INI-43	 was	 cytotoxic	 in	 nature,	 initiating	
cancer	cell	death	via	apoptosis,	and	that	it	was	able	to	inhibit	nuclear	transport,	
we	 wanted	 to	 examine	 whether	 these	 effects	 were	 due	 to	 INI-43	 interacting	
directly	with	KpnB1.		Initial	experiments	using	FRET	photo	bleaching	to	examine	
potential	INI-43	and	KpnB1	interactions	were	performed.			FRFP-KpnB1	was	used	

















used	 the	 purified	 protein	 in	 a	 circular	 dichroism	 spectral	 analysis	 of	 KpnB1.	
Titration	 of	 INI-43	 into	 the	 purified	 KpnB1	 protein	 showed	 a	 rightward	 and	
upward	 shift	 in	 the	 spectra	 at	 the	 233nm	 region.	 This	 shift	 in	 the	 spectra	was	
indicative	 of	 INI-43	 binding,	 possibly	 in	 a	 region	 rich	 in	 aromatic	 amino	 acids.		
Spectral	shifts	in	the	190nm	and	210nm	region	suggested	that	there	could	be	a	
possible	 secondary	 structural	 change	 in	 the	 KpnB1	 on	 binding	 to	 INI-43.	 The	
binding	dynamics	of	the	spectra	provided	us	with	a	preliminary	Kd	value.		
To	further	 investigate	whether	or	not	 INI-43	was	binding	directly	 to	KpnB1,	 ITC	
was	 performed	 to	 examine	 the	 thermodynamics	 involved	 in	 the	 possible	
interaction	 between	 KpnB1	 and	 INI-43.	 The	 data	 achieved	 from	 this	 analysis	
suggested	 that	 INI-43	 bound	 KpnB1	 with	 low	 affinity.	 Thermodynamic	 data	
calculations	yielded	a	best	Kd	value	of	2.99	x	10-5.		Due	to	the	low	affinity	of	the	
compound	 for	 KpnB1,	 complete	 binding	 data	 could	 not	 be	 attained,	making	 it	
difficult	to	obtain	information	on	the	types	of	interactions	involved.	
The	 reason	 for	 the	 low	 binding	 affinity	 that	 we	 observed	 is	 not	 clear.	 One	
possibility	 for	 the	 low	 binding	 affinity	 of	 INI-43	 is	 that	 INI-43	 was	 originally	
identified	using	 in	 silico	 crystal	 structures	of	KpnB1,	which	may	not	necessarily	
entirely	 reflect	 what	 would	 happen	 when	 using	 purified	 protein	 in	 in	 vitro	
analyses.	 It	 is	also	possible	that	the	binding	of	 INI-43	to	KpnB1	in	 live	cells	may	






Another	possibility	 for	 the	 low	binding	affinity	of	 INI-43	to	KpnB1	 is	 that	 INI-43	
binds	 to	 a	 small	 select	 area	 on	 a	 large	 concave	 surface	 that	 encompasses	 the	
KpnB1–Ran–Kpna2	 interaction	 area	 rather	 than	 a	 small	 binding	 pocket	 as	with	






examples,	 hence	 affinity	 of	 the	 drug	 for	 the	 protein	 is	 lower	 than	 what	 is	
considered	ideal.		
It	 is	 important	to	consider	that	we	have	limited	knowledge	on	how	this	binding	
occurs	 in	 a	 cellular	 system	 when	 other	 factors	 such	 as	 RanGTP	 or	 KpnA2	 are	
present.	 The	 presence	 of	 these	 proteins	 could	 enhance	 the	 affinity	 of	 INI-43,	
however	 confirmation	 of	 such	 an	 interaction	 would	 require	 X-ray	




While	 INI-43	 has	 shown	 promise	 as	 an	 anti-cancer	 agent	 in	 that	 it	 displays	







the	 structure	 to	 improve	 its	 binding	 affinity	 will	 be	 required.	 Crystallographic	
data	would	also	substantially	assist	in	the	generation	of	more	conclusive	KpnB1–
INI-43	 binding	 data.	 Furthermore,	 at	 present	 there	 is	 very	 little/no	 in	 the	
literature	 describing	 the	 biophysical	 nature	 of	 KpnB1–small	 molecule	
interactions,	 and	no	 crystal	 structures	of	KpnB1	bound	 to	 small	molecules.	 	 To	
our	 knowledge	 this	 is	 the	 first	 time	 a	 biophysical	 analysis	 of	 a	 small	molecule	
inhibitor	 targeted	 at	 the	 nuclear	 import	 pathway,	 specifically	 KpnB1,	 has	 been	
carried	out.			
Our	 key	 findings	 can	 be	 summarized	 as	 follows:	Using	 cell	 culture	 systems	we	




of	 both	 endogenously	 and	 exogenously	 expressed	 KpnB1,	 and	 that	 INI-43	
localises	with	 KpnB1	 after	 treatment	 of	 cells	with	 the	 drug.	 	 Using	 biophysical	
analysis	we	were	able	to	show	that	INI-43	binds	purified	KpnB1	with	low	affinity	
(within	 the	μM	range).	 	Overall,	 this	 study	has	shown	that	 there	 is	promise	 for	











































(ATCC)	 (Rockville,	 MD,	 USA):	 	 HeLa	 and	 CaSki	 cervical	 cancer	 cell	 lines	 HPV	
positive.	
6.1.2	 Cell	line	Growth	conditions	
Cells	 were	 grown	 in	 Dulbecco’s	 Modified	 Eagle’sMedium	 (DMEM)	 (Gibco,	 Life	
Technologies,	 Carlsbad,	 CA,	 USA)	 with	 10%	 heat	 inactivated	 Fetal	 Calf	 Serum	
(FCS)	(Gibco,	Life	Technologies,	Carlsbad,	CA,	USA),	100	U/ml	penicillin	and	100	
μg/ml	 streptomycin	 maintained	 at	 37°C	 in	 a	 5%	 CO2	 incubator	 and	 grown	 in	
tissue	culture	treated	dishes	Greiner	(Lasec,	Cape	Town,	South	Africa).	
6.1.2		 Drugs	
The	 compound	 INI-43	 	 (Molport,	 Riga,	 Latvia)	was	 solublised	 in	 DMSO	 (Sigma-








NFAT-luciferase	 (Addgene,	 Cambridge,	 Massachusetts,	 USA,	 plasmid	 #	 10959)	
was	 used	 to	 assess	 transcriptional	 activity	 of	 the	NFAT	 gene	of	 in	 cells	 for	 the	
dual	luciferase	assay.		A	plasmid	encoding	the	Renilla	luciferase	reporter	pRL-TK	
(Promega,	Madison,	WI,	USA)	was	used	as	an	internal	control	for	the	transfection	
efficiency	 of	 Dual	 luciferase	 assays.	 	 	 The	 pGEM-T	 Easy	 plasmid	 (Promega,	
Madison,	WI,	USA)	was	used	 to	 sub-clone	 the	PCR	products	of	 the	KpnB1	 into	
final	respective	vectors.			





use	 in	 FRET	 and	 confocal	 studies.	 	 Since	 the	 drug	 INI-43	 has	 inherent	
fluorescence	in	the	green	channel	it	is	important	we	used	a	corresponding	label	
for	 KpnB1	 in	 the	 red	 channel	 for	 confocal	 analysis.	 	 This	 also	 worked	 in	 our	
favour	 for	FRET	as	the	excitation	emission	spectra	had	an	over	 lap	with	that	of	
INI-43.	 	 Unfortunately	 negative	 controls	 displayed	 a	 colour-shift	 of	 the	 RFP-
KpnB1	from	red	to	green.	












USA).	 	 	 These	 columns	 were	 pre-packed	 with	 Ni	 sepharose	 high	 performance	
resin,	which	has	a	binding	capacity	(40mg/mL).		Column	was	run	on	AKTA	Avant	
25	 chromatography	 equipment	 (GE	 life	 sciences,	 Pittsburgh,	 USA)	 along	 with	
Unicorn	software	(GE	life	sciences,	Pittsburgh,	USA)	used	for	data	collection.	This	
setup	 belonged	 to	 Prof	 Sewel	 and	 Dr.	Weber,	 University	 of	 Cape	 Town,	 Cape	
Town,	South	Africa,	who	collaborated	with	us	this	part	of	the	project.	
For	anion	exchange	we	used	Hiprep	16/10	QFF	column	20mL	 (GE	 life	 sciences,	











For	Gel	 Filtration	we	used	 S-200	HR	 (GE	 life	 sciences,	 Pittsburgh,	USA)	 column	
which	 was	 pre-packed	 with	 120ml	 Allyl	 dextran	 and	 N,	 N’-
methylenebisacrylamide	 Gilson	 321	 pump,	 Gilson	 UV/Vis	 –	 157/159	
spectrometer	 and	 Gilson	 FC	 203B	 fraction	 collector	 (Gilson	 Inc.	 Middleton,	
Wisconsin,	 USA).	 	 This	 setup	 belonged	 to	 Prof	 Sewel	 and	 Dr	 Weber	 who	
collaborated	with	us	this	part	of	the	project.	
	



































































being	 heat	 shocked	 at	 42°C	 for	 1	minute	 then	 promptly	 returned	 to	 ice	 for	 a	
further	 2	minutes.	 	 Following	 the	 rest	 on	 ice	 950	 μl	 of	 LB	 (no	 antibiotics)	was	
added	 to	 the	bacteria/DNA	mixture	and	 the	eppendorf	 tube	was	placed	 in	 the	
orbital	shaker	for	1.5	hours	at	37°C	at	150	rpm.		Finally	the	mixture	was	plated	
on	 Luria	 agar	 plates	 made	 with	 the	 appropriate	 concentration	 of	 antibiotic	




amplify	 the	 region	of	 interest,	which	was	electrophoresed,	using	 a	1%	agarose	
gel	 and	 the	 band	 of	 interest	 removed	 and	 cleaned	 up	 using	 the	 SV	 wizard	
Gel/PCR	 clean	 up	 kit	 (Promega,	 Madison,	 WI,	 USA).	 	 	 The	 excised	 insert	 was	




The	 insert	 and	 linearized	 vector	 DNA	were	 then	 combined	 in	 a	 PCR	 tube	 and	
incubated	 at	 45˚C	 for	 5	 minutes	 in	 a	 PCR	 machine	 followed	 by	 a	 5	 minute	
incubation	 on	 ice.	 	 This	 frees	 up	 the	 sticky	 ends	 and	 makes	 ligation	 more	
efficient.	 	 The	 vector	 and	 insert	 DNA	was	 subsequently	 combined	with	 1	 x	 T4	





agar	 plates	 containing	 the	 appropriate	 antibiotic.	 A	 negative	 control	 of	 linear	
vector	 was	 also	 simultaneously	 transformed	 to	 ensure	 that	 ligation	 was	
successful.		Colonies	were	picked	at	random	from	the	ligation	plate	and	grown	in	











Easy	 vector,	 1	 x	 rapid	 ligation	 buffer	 and	 3	 units	 of	 T4	 DNA	 ligase	 (Promega,	
Madison,	WI,	USA).		This	ligation	was	performed	at	4˚C	overnight.	
The	 following	morning	 5	 μl	 of	 the	 ligation	mix	 was	 transformed	 into	 30	 μl	 of	
highly	competent	JM109	cells.			
6.2.4	 DNA	 Isolation	 via	 Mini-Prep	 -Pureyield	 mini-prep	 system	 (Promega,	
Madison,	WI,	USA)	
Several	colonies	were	picked	and	placed	 into	5mL	of	LB	containing	appropriate	
antibiotics.	 	These	were	grown	overnight	 in	an	orbital	 shaker	at	37˚C,	150	 rpm	
and	 from	 them	 glycerol	 stocks	 were	 created.	 	 The	 1.5mL	 of	 the	 remaining	
bacterial	 culture	 was	 centrifuged	 at	 13000	 rpm	 for	 1	 min	 in	 a	 bench	 top	
microfuge	to	pellet	the	cells.	 	The	supernatant	was	discarded	and	an	additional	
1.5mL	 was	 added	 centrifugation	 repeated.	 	 Once	 the	 supernatant	 had	 been	
discarded	and	 the	 cells	were	 suspended	 in	600	μl	of	 TE	buffer	 then	 lysed	with	
100	 μl	 of	 cell	 lysis	 buffer.	 	 The	 tubes	 were	 inverted	 several	 times	 to	 ensure	
complete	lysis.		350	μl	of	cold	neutralization	buffer	was	added	to	each	tube	and	
again	 the	 tubes	 were	 inverted	 until	 a	 yellow	 precipitate	 formed	 signalling	
complete	neutralization.		The	tubes	were	centrifuged	at	max	speed	for	3	minutes	
to	 remove	 the	 debris	 allowing	 for	 purification	 of	 the	 genomic	 DNA.	 	 The	DNA	
containing	supernatant	was	transferred	into	a	pureYeild	minicolumn,	which	has	a	
silica	 membrane	 to	 facilitate	 DNA	 binding	 and	 permit	 high	 quality	 DNA	
purification.		The	minicolumn	was	inserted	into	a	collection	tube	so	as	to	create	
the	minicolumn	assembly.		The	minicolumn	assembly	containing	the	supernatant	
was	 centrifuged	 at	maximum	 speed	 for	 15	 seconds	 and	 the	 flow	 through	was	
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discarded.	 	The	silica	membrane	 in	 the	minicolumn	was	washed	with	400	μl	of	
column	was	solution	to	remove	contaminants	from	the	DNA	bound	to	the	silica	
matrix,	 and	 the	 minicolumn	 was	 again	 centrifuged	 at	 maximum	 speed	 for	 30	
seconds.	 After	 transferring	 the	 minicolumn	 to	 a	 clean	 eppendorf	 the	 purified	
DNA	 was	 eluted	 from	 the	 column	 using	 20	 μl	 of	 nuclease	 free	 water.	 	 The	
minicolumn	was	again	centrifuged	as	before.	 	The	final	DNA	product	was	nano-
dropped	so	as	to	measure	the	DNA	concentration.	
1μg	of	 the	DNA	 from	each	of	 the	purified	clones	was	mapped	using	 restriction	
digests	to	ensure	that	the	plasmid	was	correct.		The	plasmid	was	mapped	using	
the	 restriction	 Enzymes.	 	 This	 clone	 was	 further	 confirmed	 using	 DNA	


















to	 enhance	 precipitation	 of	 cellular	 debris	 following	 which	 the	 solution	 was	
centrifuged	at	16	000	 x	G	 for	30	min	4°C	and	 the	DNA	containing	 supernatant	
was	preserved.	The	quiagen	tip	500	was	equilibrated	with	10mL	buffer	QBT	and	
the	DNA	 containing	 supernatant	was	 added	 to	 the	 quiagen	 tip	 and	 allowed	 to	
flow	 through.	 	 Following	 the	 addition	 of	 the	 supernatant	 the	 quiagen	 tip	 was	
washed	with	30mL	of	buffer	QC	to	remove	unwanted	carbohydrates.	The	bound	
DNA	 was	 recovered	 with	 15mL	 buffer	 QF	 and	 precipitated	 by	 the	 addition	 of	
10.5mL	room	temp	isopropanol	to	the	corex	tube	with	eluted	DNA	solution	and	
centrifuge	 at	 14	 000	 x	 G	 for	 30	min	 4°C.	 the	 DNA	was	washed	with	 5mL	 70%	
ethanol	and	centrifuge	again	at	14	000	x	G	for	10	min	4°C.		Finally	the	pellet	was	
allowed	to	air	dry	overnight	after	which	it	was	re	dissolved	in	between	200-500	




were	 grown	 in	 complete	media	 (DMEM,	 10%FCS,	 1%P/S)	 and	 seeded	 at	 1000	
cells	 per	 well	 for	 HeLa,	 3000	 cells	 per	 well	 for	 CaSki	 plated	 in	 96-well	 tissue	







crystals	 formed	 were	 solubilised	 by	 the	 addition	 of	 Solubilisation	 Solution	
Reagent	 (10	 %	 SLS	 in	 0.01	 M	 HCl).	 Absorbance	 readings	 were	 measured	 at	
595nm	 the	 following	 day	 using	 a	 BioTek	 microplate	 spectrophotometer	




cells	 were	 seeded	 into	 96-well	 tissue	 culture	 treated	 plates	 at	 1000	 and	 3000	
cells	per	well	respectively.	A	pre-determined	concentration	range	of	INI-43	(0,	5	
and	10	and	15μM)	was	selected	and	 treated	 to	each	cell	 line	 for	each	day	and	
performed	in	triplicate.	On	each	day	that	the	assay	performed,	10μL	of	MTT	was	
added	 to	 each	of	 the	 treated	wells,	 then,	 4	 hours	 later	 100μL	of	 solubilization	














kit	 (Thermo	 Fisher	 Scientific,	 Massachusetts,	 USA).	 According	 to	 the	
manufacturer’sprotocol.	
6.2.9	 Western	blot	analysis	
Protein	 was	 separated	 based	 using	 the	 Mini	 Protean	 II	 System	 (Bio-Rad,	
California,	USA)	for	SDS-PAGE.	10-40	μg	of	protein	was	separated	by	8%	or	10%	
resolving	 4%	 stacking	 gel.	 Samples	 were	 prepared	 by	 adding	 appropriate	
volumes	 of	 5X	 Laemmli	 loading	 dye	 (see	 solutions)	 following	which	 they	were	
heated/denatured	 at	 90°C	 for	 1	min.	 A	 protein	molecular	weight	markers	was	
run	concurrently	with	the	samples	to	determine	the	size	of	separated	proteins:	
all	makers	are	 listed	 in	 the	appendix.	Once	electrophoresis	was	concluded,	 the	
proteins	were	 transferred	 to	a	HybondTM-ECLTM	nitrocellulose	membrane	 (GE	
life	 sciences,	 Pittsburgh,	 USA)	 using	 the	 wet/tank	 transfer	 system	 (Bio-Rad,	
California,	 USA).	 The	membrane	 was	 blocked	 in	 a	 solution	 of	 5%	 low	 fat	milk	
powder	made	up	 in	Tris-buffered	saline	with	0.1%	Tween	(TBST).	 	Blocking	was	
performed	 for	 1	 hour	 at	 room-temperature	 on	 a	 shaker	 following	 which	 the	
membrane	was	 incubated	with	 the	 primary	 antibodies	 overnight	with	 shaking.	









substrate	 system	 (KPL	 Inc.	 Whitesci,	 Cape	 Town,	 South	 Africa).	 To	 re-probe	
membranes	 for	another	protein,	antibodies	were	stripped	 from	the	membrane	
with	 10%	 acetic	 acid,	 shaking	 for	 15	min,	 flipping	 the	 blot	 over	 half	 way.	 The	
acetic	acid	was	neutralized	by	washing	the	membrane	four	times	for	10mins	for	











PBS	 and	 then	 re-suspended	 and	 placed	 in	 sterile	 eppendorf	 tubes	 followed	by	
another	round	of	centrifugation	at	12	000	rpm	for	15	min	at	4	°C.		The	PBS	was	
removed	 and	 the	 eppendorf	 tubes	 were	 placed	 on	 ice.	 	 The	 remaining	 cells	
attached	 to	 the	 dishes	were	 harvested	 using	 RIPA	mix	 and	 a	 cell	 scraper	 as	 in	
section	 6.2.3.	 	 Following	 sonication	 and	 centrifugation	 the	 supernatant	 was	
placed	 in	 a	 clean	 pre-chilled	 eppendorf	 tube	 and	 using	 BCA	 regent	 (Thermo	
Fisher	 Scientific,	 Massachusetts,	 USA).	 	 	 PARP-1	 cleave	 was	 detected	 using	





Biotechnology,	 California,	 USA)	 and	 goat	 anti-rabbit	 horseradish	 peroxidase	
conjugate	secondary	(170-6515,	Bio-Rad,	California,	USA)	detected	with	lumiglo	
chemoluminesent	 reagent	 (KPL	 Inc.	 Whitesci,	 Cape	 Town,	 South	 Africa).	 To	
ensure	 the	 loading	 was	 accurate	 the	 blot	 was	 stripped	 using	 10%	 acetic	 acid,	
then	 re-probed	 for	 B-tubulin	 and	 detected	 with	 lumiglo	 chemoluminesent	
reagent.	 	 Densitometric	 analysis	 was	 performed	 using	 image	 J	 subtracting	 the	
loading	control	from	the	results	to	create	a	quantitate	result.	
6.2.11	 Ability	of	INI-43	to	inhibit	Nuclear	Import-NFAT	assay	
30	000	HeLa	cells	were	plated	per	well	 in	24-well	 tissue	culture	 treated	plates,	
and	 transfected	 with	 50	 ng	 GFP-NFAT	 plasmid	 (Addgene,	 Cambridge,	
Massachusetts,	USA,	plasmid	#	24219,	gift	of	 Jerry	Crabtree	 (34)),	50	ng	NFAT-
luciferase	 (Addgene,	 Cambridge,	Massachusetts,	 USA,	 plasmid	 #	 10959,	 gift	 of	




Aldrich,	 Johannesburg,	 South	 Africa)	 and	 1.3	 μM	 Ionomycin	 (Sigma-Aldrich,	










6.2.12	 Confocal	 microscopy-Effects	 of	 INI-43	 on	 Endogenous	 Expression	 of	
Kpnβ1	
HeLa	cells	were	grown	on	glass	coverslips	in	1000	mm	dishes	seeded	at	a	density	
of	 600	 000	 cells	 per	 well	 in	 a	 6	 well	 tissue	 culture	 treated	 plate	 in	 complete	
media	 (DMEM,	 10%FCS,	 1%P/S).	 Once	 the	 cells	 had	 settled	 they	were	 treated	
with	10	μM	INI-43	for	1.5	or	3	hours.	For	controls,	equivalent	volumes	of	DMSO	
(Sigma-Aldrich,	 Johannesburg,	 South	 Africa)	 were	 used.	 Subsequent	 to	
treatment,	media	was	 removed	 and	 the	 cells	 washed	with	 1	 x	 PBS	 then	 fixed	
with	 4%	 paraformaldehyde	 followed	 by	 3	 x	 5	 minute	 washes	 in	 1	 x	 PBS.		
Following	 fixation	 the	 cells	 were	 permeabliized	 with	 0.5%	 triton	 X	 100	 and	
subsequently	washed	 in	1	 x	PBS	 for	5	mins.	 	 50mM	NH4Cl	 in	PBS	was	used	 to	
quench	 for	 5	 minutes	 then	 blocking	 was	 performed	 using	 0.2%	 gelatin.	
Immunofluorescence	 analysis	was	 performed	using	 1:100	 Kpnβ1	 antibody	 	 (sc-
11367,	Santa	Cruz	Biotechnology,	California,	USA)	in	0.2%	gelatine	incubated	for	















facilitate	 the	 cloning	 of	 the	 Kpnβ1	 fragment	 into	 the	 final	 plasmid.	 	 These	
particular	restriction	enzymes	were	chosen	as	they	do	not	cut	the	KpnB1	or	the	
shuttle	vector	pGEM®-T	Easy		
The	 PCR	was	 performed	 using	 the	 primers	 (10pmol	 of	 each)	 to	 amplify	 10ng	 of	




Cycle	1	 	 95˚C		 5min	
Cycle	2	 	 95˚C		 30sec	
																								60˚C	 30sec	 						35	cycles	
																							72˚C	 3	min	
Cycle	3	 	 72˚C	 7min	
Cycle	4	 		 4˚C	 ∞	
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Coli	 JM109	competent	 cells	 (Promega,	Madison,	WI,	USA),	a	blue/white	 screen	




linearized	 using	 the	 same	 restriction	 enzymes.	 	 The	 digested	 products	 were	




The	 ligation	mix	was	 transformed	 into	E.	Coli	 JM109	competent	cells	as	before	











The	 pmKate-KpnB1	 was	 transfected	 into	 HeLa	 cells	 to	 test	 for	 transfection	
efficiency.		450	000	cells	per	dish	in	100	mm	cell	culture	dishes		(Greiner,	Lasec,	
Cape	 Town,	 South	 Africa).	 and	 grown	 in	 complete	 media	 (DMEM,	 10%FCS,	
1%P/S).	 	 	 Cells	 were	 left	 to	 settle	 overnight.	 	 24	 hours	 later,	 the	 cells	 were	
transfected	 with	 pmKate-Kpnβ1.	 	 2.9μg	 of	 plasmid	 DNA	 was	 added	 to	 200μL	





The	 process	was	 repeated	 but	 this	 time	 glass	 cells	were	 grown	 on	 glass	 cover	
slips,	 transfected	 with	 pmKate-KpnB1	 and	 on	 day	 3	 treated	 for	 various	 time	
intervals	with	 INI-43	 then	 fixed	using	4%	paraformaldehyde	and	 left	 in	1	x	PBS	
until	 viewed	 with	 confocal	 microscopy.	 Images	 were	 captured	 using	 a	 Zeiss	
inverted	fluorescence	microscope	under	100	X	oil	immersion.		
6.2.14	 FRET	Photo	Bleaching	





with	 10	 μM	 INI-43	 for	 30	 and	 45	 minutes	 then	 subsequently	 fixed	 using	 2%	





Zeiss	 LSM	510	Meta	confocal	microscope.	Regions	of	 interest	 (ROIs)	 containing	
cells	that	both	exhibited	INI-43	fluorescence	and	expressed	mKate2-KpnB1	were	
selected	for	bleaching.	The	561	nm	laser	line	was	used	to	excite	and	bleach	the	
far-red	 signal.	 Bleaching	was	 achieved	 by	 20	 intterations	 of	 the	 laser	 over	 the	





Zen	 Blue	 software	 (Zeiss)	 was	 used	 to	 convert	 the	 confocal	 images	 into	 FRET	
images.	
6.2.15	 Sub	cloning	of	KpnB1	into	pET-28b	




wizard	 gel	 and	 PCR	 clean	 up	 kit	 (Promega,	 Madison,	 WI,	 USA).	 The	 separate	
fragments	 were	 A-tailed	 in	 preparation	 for	 insertion	 to	 the	 shuttle	 plasmid	
pGEM-T-EASY.	 	 Following	 the	 A-tailing	 process,	 the	 separate	 fragments	 were	
ligated	 into	 pGEM-T-EASY	 shuttle	 plasmids	 at	 4°C	 over	 night	 and	 transformed	
into	 JM109	 bacterial	 cells.	 Once	 in	 pGEM-T-EASY,	 a	 blue/white	 screen	 was	
performed	 and	 the	white	 colonies	were	 picked	 and	 screened	 for	 inserts	 using	





inserts	 were	 excised	 using	 BamH1	 and	 SacII	 restriction	 enzymes	 (Fermentas	




We	were	 gifted	 with	 the	 plasmid	 pIB-GFP	 (Importin-Beta-GFP)	 kindly	 donated	
from	 M.	 Ciciarello	 et	 al	 (2004).	 	 Primers	 were	 designed	 so	 as	 to	 allow	 for	
amplification	 of	 the	 fragment	 of	 interest	 (KpnB1)	 via	 PCR.	 	 Restriction	 sites	
BamH1	and	Xma1	were	 incorporated	onto	 the	 5’	 ends	of	 the	primers	 so	 as	 to	
facilitate	 the	 cloning	 of	 the	 KpnB1	 fragment	 into	 the	 final	 plasmid.	 	 These	
particular	restriction	enzymes	were	chosen	as	they	do	not	cut	the	KpnB1	or	the	
shuttle	vector	pGEM®-T	Easy	(Promega,	Madison,	WI,	USA).		The	stop	codon	had	













Cycle	1	 	 95˚C		 5min	
Cycle	2	 	 95˚C		 30sec	
45˚C	 30sec	 	 35	cycles	
		 	 	 72˚C	 3	min	
Cycle	3	 	 72˚C	 7min	
Cycle	4	 		 4˚C	 ∞	
The	PCR	products	were	electrophoresed	on	a	1%	agarose	gel	using	the	O’Gene	
ruler	 ladder	 mix	 marker	 (Fermentas	 Thermo	 Fisher	 Scientific,	 Massachusetts,	
USA)	 to	 specify	 the	 size	 of	 the	 bands	 present.	 	 PCR	 product	was	 then	 excised	











enzyme	 BamHI	 (Fermentas	 Thermo	 Fisher	 Scientific,	 Thermo	 Fisher	 Scientific,	
Massachusetts,	USA)	 and	Xma	 I	 (NEB,	 Thermo	Fisher	 Scientific,	Massachusetts,	
USA)	 and	 re-ligated	 into	 the	 final	 plasmid	pGEX-6P.	 	Once	again	 ligations	were	
transformed	and	the	DNA	mapped	via	restriction	digest	and	DNA	fingerprinting.			
6.2.17	 Assessing	GST-KpnB1	protein	induction		
A	 10mL	 starter	 culture	 using	 TB	 100μg/mL	 Ampicillin	 (Sigma-Aldrich,	
Johannesburg,	South	Africa)	was	grown	for	2-5	hours	before	transferring	to	a	100	
mL	 culture	 (TB	100μg/mL	Ampicillin)	which	was	 grown	over	night	 in	 an	orbital	
shaker	 at	 37˚C	 200	 rpm.	 	 The	 following	 morning	 50	 mL	 was	 removed	 as	 un-
induced	 cells	 and	 the	 bacteria	 collected	 by	 centrifugation	 at	 6000	 x	 G	 for	 10	





A	 10	 mL	 starter	 culture	 was	 grown	 in	 TB	 (30μM	 Kanamycin)	 (Sigma-Aldrich,	
Johannesburg,	South	Africa)	over	night	at	37˚C	with	shaking	in	a	100mL	flask	the	
following	 morning	 this	 starter	 culture	 was	 transferred	 to	 fresh	 TB	 with	 fresh	










of	 sonication	 can	 be	 performed	 here	 then	 filtration)	 a	 sample	 of	 the	 filtered	
cleared	 lysate	was	maintained.	 The	 protein	was	 purified	 using	 HisTrap	HP1	ml	
column.		The	column	was	equilibrated	by	washing	5	x	column	volumes	with	wash	




with	 shaking	 in	 a	 100mL	 flask	 the	 following	 morning	 this	 starter	 culture	 was	
transferred	to	fresh	TB	with	fresh	30μM	(Kanamycin)	and	grown	until	OD600	is	
between	 0.6.	 The	 culture	 was	 Induced	 with	 1mM	 IPTG	 (final	 concentration	
0.1mM)	 and	 continued	 to	 grow	 at	 25˚C	 for	 a	 further	 24	 hours.	 Cells	 were	
harvested	at	5000	rpm	for	20	min	and	the	supernatant	discarded.			
A	 lysate	was	prepared	by	dissolving	Half	an	EDTA-free	protease	 inhibitor	 tablet	
(Sigma-Aldrich,	 Johannesburg,	 South	 Africa)	 into	 50	 mL	 of	 buffer	 A	 (an	 anion	







ethanol	 bath,	 effectively	 ensuring	 a	 cold	 temperature	 was	 maintained.		
Sonication	was	carried	out	using	15	second	pulses	at	40W	with	15	second	 rest	





of	 sonication	 can	 be	 performed	 here	 then	 filtration)	 a	 sample	 of	 the	 filtered	
cleared	lysate	was	maintained.	The	pellet	was	homogenized	with	40ml	of	buffer	
A	 then	a	 sample	 taken.	At	 this	point	 it	 is	 important	 to	 run	an	SDS-PAGE	gel	 to	
assess	the	induction	and	lysis.		
High-resolution	anion	exchange	column	(QHP	Seph	20mL)	was	equilibrated	with	
4	 x	 column	 volume	with	 buffer	 A	 (low	 salt)	 at	 a	 flow	 rate	 of	 2.5	mL/min.	 The	





system	 partnered	 to	 a	 Gilson	 321	 pump,	 aUV/Vis-155	 spectrophotometer,	 as	
well	 as	 a	Gilson	 FC	 204	 fraction	 collector.	 Fractions	were	 electrophoresed	 and	
probed	 for	 KpnB1	 using	 western	 blot	 analysis,	 then	 fractions	 of	 interest	 were	





Pittsburgh,	 USA)	 and	 run	 once	 more	 through	 the	 anion	 exchange	 to	 remove	
contaminants	 before	 again	 being	 examine	 by	 SDS-PAGE	 and	 western	 blot.	 	 A	
polishing	step	was	performed	using	Gel	filtration	was	performed	using	Superdex	
200	10/300	GL	column	equilibrated	with	4	column	volumes	of	50mM	Hepes	 in	






terrific	 broth	 overnight	 (200ml)	 while	 the	 remaining	 800mL	 was	 placed	 in	 an	
incubator	to	keep	it	warm	for	the	following	morning.		First	thing	in	the	morning	
the	starter	culture	was	mixed	with	 the	 remaining	warm	broth	and	 left	 to	grow	
for	 1	 hr	 30	 minutes	 until	 the	 OD600	 was	 approximately	 1.	 	 The	 culture	 was	
induced	 with	 1mL	 of	 1mM	 IPTG	 (Promega,	 Madison,	 WI,	 USA).)	 and	 the	
temperature	was	 dropped	 to	 25˚C	 for	 further	 24	 hrs	 following	which	 the	 cells	
were	harvested	via	centrifugation	at	6000	rpm	for	10mins	at	4˚C.		The	cell	pellet	
was	 slowly	 frozen	 to	 -80·C	 in	 the	 freezer	 overnight	 then	 used	 in	 protein	
purification.			
During	the	purification	process,	the	bacterial	cell	pellet	was	first	allowed	to	thaw	




purification	 was	 being	 done	 for	 circular	 dichroism	 as	 this	 process	 effects	 the	
reading	of	 the	CD.	 	Only	 glass	or	non-leaching	plastics,	 such	as	 those	made	by	
Eppendorf®	 (Eppendorf,	 Hamburg,	 Germany)	 were	 used.	 	 Ordinary	 plastic	 tips	
and	 eppendorfs	 were	 found	 to	 leach	 into	 the	 protein	 and	 cause	 errors	 in	 the	
results	particularly	circular	dichroism.		Similarly	triton-x	was	not	used	either	as	it	
absorbs	 highly	 at	 the	 280nm	 range	 throwing	 out	 the	 readings.	 	 For	 similar	
reasons	we	could	not	use	DTT	as	this	caused	fluctuations	 in	the	 ITC	readings	 in	
the	form	of	a	baseline	shift.	
Once	 the	 bacterial	 cell	 pellet	 was	 completely	 re-suspended	 i.e.	 no	 solid	 cell	
clumps	remaining,	the	bacterial	mixture	was	sonicated	while	in	an	ice	bath	for	30	
second	 intervals	 until	 lysis	 occurred.	 	 The	 next	 step	 was	 to	 collect	 the	 crude	
protein	via	centrifugation	which	was	performed	at	12	000	rpm	for	10	min	at	4˚C.		
The	 protein	 containing	 supernatant	 (crude	 lysate)	 was	 kept	 for	 further	
purification	and	the	cell	debris	pellet	was	discarded.	
The	 crude	 lysate	 collected	 as	 above	 was	 further	 purified	 using	 amicon	 ultra	
concentration	device	 (GE	 life	 sciences,	 Pittsburgh,	USA).	 	 The	 crude	 lysate	was	
concentrated	 down	 to	 2mL	 to	 maximise	 the	 capacity	 of	 the	 resin	 in	 the	 next	




on	 a	 rotator	 at	 room	 temperature	 for	 4	 hours,	 then	moved	 to	 the	 cold	 room	
(4˚C)	and	continue	to	rotate	overnight.			
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The	 following	 morning,	 collection	 of	 the	 flow	 through	 was	 carried	 out	 via	
centrifuging	at	 5000	 rpm	 for	5min,	 removing	 the	 supernatant.	A	 small	 amount	
was	retained	for	analysis.	The	resin	was	then	washed	2	times	with	5mL	cold	1	x	
PBS	 pH	 7.5.	 To	 elute	 the	 protein	 form	 the	 resin	 a	 solutions	 of	 50mM	 reduced	




The	 purified	 protein	 was	 electrophoresed	 using	 SDS-PAGE	 and	 stained	 with	
coomassie	brilliant	blue	so	as	to	examine	the	efficiency	of	the	purification.		Crude	
fractions,	flow	through,	washes	and	all	elutions	were	run	the	gel	along	with	BSA	
standards.	 	 This	 enabled	 quantification	 of	 the	 amount	 of	 KpnB1	 using	 image	 J	
densitometry	software.		The	purified	protein	was	then	used	for	analysis	such	as	
circular	 dichroism,	 isothermal	 calorimetry	 and	 thermal	 shifts.	 	 These	 analyses	
were	done	in	the	presence	and	the	absence	of	the	test	compound	INI-43.	
6.2.21	 Circular	Dichroism	
Purified	protein	was	 concentrated	and	 the	 reduced	glutathione	 removed	using	
amicon	 ultra	 30K	 spin	 column	 (GE	 life	 sciences,	 Pittsburgh,	 USA).	 	 The	 final	
concentration	 of	 KpnB1	was	 quantified	 using	 BCA	 analysis	 and.	 	 Following	 this	
the	protein	was	 run	 through	sephadex	G10	 resin	 to	degas	 it	 in	preparation	 for	
circular	dichroism.		This	final	protein	solution	was	made	up	to	a	concentration	of	
0.2μg/mL	with	milliQ	water.	 	Circular	Dichroism	was	performed	using	Chirascan	








DMSO	absorbs	 strongly	within	 the	280nm	range	causing	anomalies	 in	 the	data	
generated.	 	 Initially	 a	 reading	 of	 the	 protein	 on	 its	 own	 was	 taken	 then	







concentrations	at	 specific	wavelengths,	and	plotting	 these	as	 individual	graphs.		
Binding	isotherms	were	also	plotted	individually	for	various	wavelengths	to	gain	
insight	 into	 the	 affinity	 of	 INI-43	 for	 KpnB1.	 This	 data	 analysis	 used	 both	
Microsoft	Excel	and	Graph	Pad	Prism.	
Raw	CD	data	was	captured	and	saved	 into	Microsoft	Excel.	 	 Solvent	effect	was	
subtracted	from	the	raw	data.	Data	points	for	a	desired	wavelength	were	chosen	
over	increasing	concentration	of	INI-43		




To	 create	 the	 scatchard	 plot,	 the	 data	 was	 transformed	 to	 pharmacology	 and	
biochemistry	settings	selecting	scatchard	and	a	new	graph	was	created.	
The	Bmax	was	divided	by	the	Kd	to	create	the	line	of	best	fit.		





The	 purified	 protein	was	 used	 in	 further	 binding	 experiments	 in	 ITC	 using	 the	
MicroCal™	 iTC200	System	(GE	 life	 sciences,	Pittsburgh,	USA).	 	The	 test	cell	was	
washed	 with	 buffer	 (See	 solutions)	 then	 protein	 was	 added	 at	 the	 desired	
concentration.	 	 Next	 the	 syringe	 was	 loaded	 with	 drug	 at	 the	 desired	
concentration	and	set	to	the	closed	position.	 	The	tip	of	the	syringe	was	gently	
cleaned	 then	 inserted	 into	 the	 test	 cell	 and	 the	 program	was	 setup	 to	 run	 21	























• Data	 points	 for	 a	 desired	 wavelength	 were	 chosen	 over	 increasing	
concentration	of	INI-43		
• Saturation	 binding	 curves	 were	 created	 using	 GraphPad	 Prism	 using	
single	 XY	 points	 graph	 and	 fitting	 the	 data	 to	 non-linear	 regression	 curve,	 one	
binding	site	(hyperbola).	
• To	create	the	scatchard	plot,	the	data	was	transformed	to	pharmacology	
and	biochemistry	settings	selecting	scatchard	and	a	new	graph	was	created.	
• The	Bmax	was	divided	by	the	Kd	to	create	the	line	of	best	fit.		
• By	selecting	data	tables	and	creating	a	new	data	table	(Renamed	Y	and	X	
intercepts)	
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I	enter	the	following	X=	0	;	Y=	Bmax/Kd	
																								X=Bmax;	Y=0	
• Format	the	scatchard	Line	data	connecting	the	two	scatchard	 intercepts	
with	a	line	and	adding	this	scatchard	plot	to	the	binding	isotherm.	
6.3		 Solutions	
6.3.1	 DNA	Solutions	
6.3.1.1	Agarose	gel		 1%	
Agarose	1g,	1x	TAE	buffer		100mL,	Microwave	until	completely	melted	and	add	
5ul	of	ethidium	bromide	
6.3.1.2	DNA	Loading	Buffer	(6x)	
250mM	Tris	(pH	6.8),	6%	SDS,	0.005%	bromophenol	blue,	40%	glycerol	10%	B-
mercapterethanol.	
6.3.1.3	TAE	Buffer	50x	 	 1L	
0.04M	Tris	acetate,	0.0001	EDTA	pH	8.		For	each	litre	of	solution:	242	g	Tris	Base	
(MW=121.1)	57.1	mL	Glacial	Acetic	Acid	10	mL	0.5	M	EDTA	mix	Tris	with	stir	bar	
to	dissolve	in	about	600	mL	of	ddH2O.	add	the	EDTA	and	Acetic	Acid,	pH	to	8.0.	
bring	final	volume	to	1	L	with	ddH2O.	store	at	room	temperature	
6.3.1.4	TE	buffer	 	 100mL	
10mM	Tris	pH8,	1mM	EDTA	pH	8	(Autoclcave)	
	 	 	
	
	
	
147	
	
6.3.2	 Tissue	culture	solutions	
6.3.2.1	PBS	
137	mM	NaCl,	2.7	mM	KCl,	4.3	mM	Na2HPO4.7H20	(pH7.4),	1.4	mM	KH2PO4	
Autoclave	the	solution.	
6.3.2.2	Trypsin-EDTA	
0.05%	trypsin,	137	mM	NaCl,	2.7	mM	KCl,	4.8	mM	Na2HPO4.2H2O,	1.4	mM	
KH2PO4,	10mM	EDTA	(pH	8.0)	
6.3.2.3	16%	Paraformaldehyde	(PFA)	
Dissolve	16	g	Paraformaldehyde	in	80	ml	dH20	by	stirring	at	60°C	for	1	hour,	
ensuring	the	temperature	does	not	exceed	60°C.	Add	drops	of	10	M	NaOH	until	
the	solution	clears	and	pH	to	7.	Make	the	solution	up	to	100	ml	and	filter-sterilize	
using	a	0.45μm	filter.	Store	at	-20°C.	
6.3.2.4	Cell-freezing	media	
70%	DMEM,	20%	FCS,	10%	DMSO	
6.3.2.5	MTT	 Reagent	 (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium	
bromide)	Sigma	(M2128)	
Dissolve	100	mg	of	MTT	reagent		in	20mL	of	1xPBS	by	vortexing	ad	heating	in	
37˚C	water	bath.	Filter	sterilize	using	a	0.2uM	syringe	protect	from	light	and	
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Store	at	4˚C	for	up	to	1	month.	
6.3.2.6	MTT	Solubilisation	Solution	 250mL	
10%	SDS	in	0.01M	HCl	store	at	room	temperature	 	 	
6.3.3	 WESTERN	BLOT	SOLUTIONS	
6.3.3.1	RIPA	Buffer		 	 200mLs	
150mM	NaCl,	10mM	Tris	pH7	,	1%	triton	X-100,	100%	triton	X-100,	0.1%	SDS,	10%	
SDS.		(Autoclave	and	store	at	4°C)	
6.3.3.2	RIPA	mixture	Solution	
RIPA	Buffer	45uL,	10	x	PI	5uL,	Na2VO3	0.05	
6.3.3.3	10X	Running	Buffer	
Dissolve	40	g	Glycine,	63.2	g	Tris	and	10	g	SDS	in	1000	ml	dH20.	
6.3.3.4	10X	Transfer	Buffer	
Dissolve	144	g	Glycine	and	38	g	Tris	in	1000	ml	dH20.	
6.3.3.5	1X	Transfer	Buffer	
Dilute	100	ml	10X	Transfer	Buffer	with	700	ml	dH20	and	add	200	ml	methanol	or	
Isopropanol.	
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6.3.3.6	Normal	Coomassie	Staining	Solution	
50%	Methanol,	10%	Acetic	Acid,	0.05%	Coomassie	Brilliant	Blue	
6.3.3.7	Normal	Destain	
5%	Methanol,	7%	Acetic	Acid	
6.3.3.8	TBST	
50	mM	Tris	(pH	7.5),	150	mM	NaCl,	0.1	%	Tween-20	
6.3.4	 Protein	Purification	Solutions	
6.3.4.1	Luria	Agar	 	 1L	
Tryptone	10g,	yeast	extract	5g,	NaCl	10g,	agar15g,	autoclave.	Cool	to	about	28	
degrees	calcium	and	add	desired	antibiotics	and	pour	plates	
*NB	to	make	plates	with	IPTG	and	XGAL	spread	100ul	of	1M	IPTG	and	20uL	
50mg/mL	XGAL	on	to	plates	and	let	them	soak	in	for	at	least	an	hour	before	
plating	
6.3.4.2	Ampicillin	(100	mg/ml)	
Dissolve	100	mg	Ampicillin	in	10	ml	dH20.	Filter-sterilize	and	store	at	-20°C.	
6.3.4.1	X-gal	(50	mg/ml)	
Dissolve	50	mg	X-gal	in	1	ml	DMSO.	Protect	from	the	light	and	store	at	-20°C.	
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6.3.4.2	IPTG	(0.1	M)	
Dissolve	72	mg	IPTG	in	3	ml	dH20.	Filter-sterilize	and	store	at	4°C.	
6.3.4.3	Luria	Broth	 1L	
Tryptone	10g,	yeast	extract	5g,	NaCl	10g,	agar15g,	autoclave.		Add	antibiotics	
when	cool.	
6.3.4.4	SOC	Medium	 50ml	
0.5%	yeast	extract,	2%	tryptone	10mM	NaCl,	2.5mM	KCl	20mM	MgSO4.	
Autoclave.	Once	cool	add	20%	glucose	solution.		
6.3.4.5	Terrific	Broth	(TB)	1lL	
Tryptone	12g,	yeast	extract	24g,	glycerol	4mL,	make	up	to	900ml	with	distilled	
H2O.	Autoclave	
6.3.4.6	10X	Potassium	butter	for	TB	
0.72M	K2HPO4,	0.169M	KH2PO4	pH	7.	Autoclave		
Add	100mL	of	potassium	buffer	to	TB	broth	just	before	use.	
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6.3.5	 His	tag	purification	solutions	
6.3.5.1	Potassium	Buffer	
0.2M	NaH2PO4 2H2O,	0.2M	Na2HPO4.	Take	the	0.2	Na2HPO4		and	titrate	in	the	
0.2M	NaH2PO4 2H2O	to	make	up	to	a	pH	of	8.	This	is	the	0.2M	potassium	buffer	
pH	8	
6.3.5.2	Binding	buffer	
50mM	Potassium	buffer,	300mM	NaCl.	pH	8	
6.3.5.3	Wash	Buffer	
50mM	Potassium	buffer,	300mM	NaCl,	200mM	Imidazole.	pH	8	
6.3.5.4	Elution	buffer	
50mM	potassium	buffer,	300mM	NaCl,	500mM	imidazole.	pH	8	
6.3.6	 Ion	Exchange	solutions	
6.3.6.1	Buffer	A:	50mM	Tris	pH8,	50mM	NaCl	
6.3.6.2	Buffer	B:	50mM	Tris	pH	8,	1M	NaCl	
6.3.6.3	Lysis	buffer	
Add	half	an	EDTA	free	protease	inhibitor	tablet	to	50mL	of	buffer	A		
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6.3.7	 GST	Tag	Purification	solutions	
6.3.7.1	Lysis	buffer		
Add	half	an	EDTA	free	protease	inhibitor	tablet	to	50mL	1	x	PBS	
6.3.7.2	Wash	Buffer	
1	x	PBS	
6.3.7.3	Elution	Buffer	
50mM	Reduced	glutathione	in	PBS	pH	7.5-8	
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Appendix	
Figure	1:	KpnB1	was	cloned	from	pGEX-KpnB1	into	pmKate-KpnB1.		Schematic	
rendition	of	cloning	process	
pmKate-
Kpnβ1	
72000Kb	
mKate2	
SacII	
KpnB1	
BamH1 
Kan/Neo	
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Figure	2:	KpnB1	was	cloned	from	pGEX-	KpnB1	into	pET-28b.		Schematic	
rendition	of	cloning	process	to	create	C-	and	an	N-His	tagged	clones.		
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Figure	3:	KpnB1	was	cloned	from	Importin	B	GFP	into	pGEX-KpnB1.		Schematic	
rendition	of	cloning	process	
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